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Abstract – The role of GPR65 and GALC in Multiple Sclerosis 
Wenjia Liao 
Genome-wide association studies have identified an extensive catalogue of unequivocally 
associated genetic variants, each of which provides a clue to the aetiology of multiple sclerosis 
(MS). Unfortunately, for the vast majority of these quite how the genetic change contributes to 
the development of the disease is unknown. However, preliminary work undertaken by one of 
my predecessors suggested that the functionally relevant variant underlying the association 
identified on chromosome 14q31.3 might exert its effect by influencing T cell activation in a 
pH dependent manner. From a genetics perspective the ImmunoChip study showed that the 
lead most strongly associated single nucleotide polymorphism (SNP) tagging this association 
was rs74796499, which lies in a region of genome containing two protein coding genes; the 
lysosomal enzyme galactosylceramidase (GALC) and acid sensing surface receptor G-protein 
coupled receptor 65 (GPR65). In my thesis I attempted to validate and replicate this finding, 
and also to explore the possibility of other pH dependent effects of this SNP. 
 
In order to undertake this work, I first developed a system capable of maintain cultured cells at 
a stable pH for prolonged periods. Using this system I was able to show that the activation of 
human lymphocytes to stimulation with anti-CD3/CD28 antibodies is maximal at neutral pH 
and reduced in both acidic and alkaline conditions. Unfortunately, I was unable to replicate the 
provisional finding that carrying the protective allele at rs74796499 resulted in greater 
inhibition of CD25 expression in acidic conditions. However, I did observe nominally 
significant evidence that the expression of the early activation marker CD69 was induced by 
culturing cells in unstimulated but acidic conditions, and that this expression was highest in 
individuals carrying the protective allele at rs74796499. In my first attempt to validate and 
replicate this new finding I not only found further evidence to support this effect on CD69 in 
unstimulated cells but also found nominally significant evidence that the expression of 
lactosylceramide (LacCer, CD17) was lower in ex-vivo cells from individuals carrying the 
protective allele at rs74796499. Unfortunately, in my final confirmatory experiments I was 
unable to replicate either of these effects. In summary despite carefully studying over 160 
healthy subjects, I was unable to find any statistically significant evidence that rs74796499 
genotype exerts any effects the expression of either CD25, CD69 or LacCer in ex-vivo cells or 
stimulated and unstimulated cells cultured under a range of pH conditions.  
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Chapter 1: Introduction 
1.1 Multiple sclerosis 
 Pathogenesis of multiple sclerosis 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) which 
in the developed world is a common cause of chronic neurological disability in young adults 
[1]. MS most frequently begins in the third of fourth decade of life and affects women more 
often than men [2]. Pathologically the disease is characterised by patchy inflammatory 
demyelination of the central nervous system accompanied by neurodegeneration [3]. Myelin is 
a lipid-rich membrane covering axons that is generated and maintained by oligodendrocytes. 
Damage or loss of myelin, and/or its supporting oligodendrocytes, impairs the ability of axons 
to transmit electrical impulses and thereby results in neurological dysfunction. As time passes 
the disease leads to axonal loss and neurodegeneration that results in the progressive 
accumulation of irreversible disability. Common symptoms include weakness, sensory upset, 
balance problems, sphincter disturbance and fatigue. 
 
The clinical course of MS has been classified into four main types. In the majority of cases 
(80%) patients begin with what is referred to as relapsing-remitting MS (RRMS) where they 
have episodes of neurological upset, typically about one per year, from which recovery is 
generally complete [1, 4]. After a time these relapses tend to become less common but instead 
the patients have increasing accumulation of disability (secondary progressive MS). In 15-20% 
of patients, the disease progresses from onset with little to no recovery periods and 
accumulation of disability (primary progressive MS) [5]. Approximately 5% of patients have 
progressive-relapsing MS (PRMS) in which they have progressive disease from the onset but 
this is punctuated by occasional relapses [5]. Although the pathogenesis of MS remains unclear, 
available evidence suggests that the disease results from the effects of environmental factors 
acting in genetically susceptible individuals [6].  
 
 Environmental factors 
The prevalence of MS varies across the world, being highest in temperate parts of the globe, 
such as North America and Europe (approximately 1:1000 in the UK) [7], and lowest in tropical 
areas, such as Asia and Africa [8]. Migration studies have shown that risk increases in people 
moving from low-risk to high-risk areas, and vice versa, particularly if they move before 
puberty (age 15 years) [9-11], with the result that changes in risk are greatest in second 
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generation migrants and minimal in adults from the first generation [12]. These data confirm 
the involvement of environmental factors in the development of MS but don’t provide much 
information about what these factors might be. Both infective and non-infective factors have 
been considered [13, 14].  
 
The role of viral infection in the pathogenesis of MS remains uncertain. Epstein-Barr virus 
(EBV) infection has been reported to be strongly associated with the susceptibility of MS [15] 
and increased levels of EBV antibodies are found in the serum and cerebrospinal fluid (CSF) 
in MS patients [16-18]. It has been suggested that EBV infection might generate T cells that 
cross-react with CNS antigens, or that MS might represent bystander damage caused by CD8+ 
T cells attacking EBV infected autoreactive B cells [19]. A role for human herpesvirus 6 (HHV-
6) has also been suggested, particularly in disease relapses and progression [20], with HHV-6 
DNA and antigens found in MS plaques and oligodendrocytes [21]. Non-infective factors such 
as sunlight/vitamin D [22, 23], smoking [23] and diet [24] have also been implicated, however 
no environmental risk factor has been firmly established as being unequivocally essential for 
the development of MS. 
 
 Genetic factors 
Epidemiological studies have consistently identified clustering of the disease in families, with 
twin studies confirming that much of this clustering relates to shared genetic factors. In the 
Canadian twin study for example, researchers found that recurrence risk was 25.9% for 
identical (monozygotic) twins compared with just 2.3% for fraternal (dizygotic) twins [25]. 
Consistent results have been found in other populations, such as the Danish [26], UK [27] and 
Italian populations [28]. In a unique adoption study, only one case of MS was found among 
1201 first-degree non-biological relatives of patients who had been adopted at an early age, 
which is equal to the general population prevalence rate (0.1%) for MS [29].  
 
Association with variation in the Human Leukocyte Antigen (HLA) genes from the Major 
Histocompatibility Complex (MHC) was identified more than 40 years ago [30-32]. 
Subsequent studies of the MHC have shown that although many variants from this region show 
association with MS, most of these associations are secondary to linkage disequilibrium (LD) 
with HLA-DRB1*15:01 the strongest genetic risk factor associated with MS identified to date 
[33-36]. The primary function of the HLA genes is to provide a means for the immune system 
to distinguish self, the body’s own proteins and cells, from foreign material such as pathogens. 
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How and why this particular allele of DRB1 increases the risk of MS remains unknown, but 
most likely relates in some way to antigen presentation. 
 
In the last 10 years genome-wide association studies (GWAS) have identified more than two 
hundred non-MHC common variants that increase the risk of developing MS, each of which 
exerts only a minor individual effect on risk [37]. Most of these associated variants lie close to 
immunologically relevant genes but how they affect the immune system is only known for a 
very few loci. For example, the risk allele of rs6897932 which maps within the spliced exon 6 
of IL-7Rα, the gene for the α subunit of the interleukin 7 (IL-7) receptor, has been shown to 
increase the proportion of soluble as opposed to membrane bound receptor, and thereby inhibit 
IL-7 signalling [38, 39]. More recently evidence for interaction of this variant with rs2523506 
from the DDX39B gene has emerged extending our understanding of the mechanism 
underlying this shift in alternate splicing [40]. Although many of the MS associated 
susceptibility variants also influence the risk of developing other autoimmune diseases [41], 
and thus presumably exert their effects by shifting the immune system towards autoreactivity, 
some of the risk variants appear to only influence the risk of developing MS. It seemed to me 
that these MS specific variants might be more revealing about why MS rather than some other 
autoimmune disease develops, and might therefore be interesting targets for functional analysis.  
 
 Current disease modifying therapies for MS 
Currently, there is no cure for MS, but in the last 20 years a range of disease modifying 
therapies (DMTs) have emerged which modulate or suppress the immune system and thereby 
reduce the inflammatory activity of the disease (in particular the number of relapses). The first 
DMT licenced for patients with relapsing-remitting MS was β-interferon (IFN-β) which 
reduces proinflammatory type 1 T helper (Th1) cells and increases anti-inflammatory type 2 T 
helper (Th2) cells [42-44]. Another key effect of IFN-β is inhibition of matrix 
metalloproteinase (MMPs) expression which reduces the number of inflammatory 
macrophages that cross the blood brain barrier [45]. A clinical study showed that MS patients 
treated with IFN-β have increased levels of soluble CD73, a known neuroprotective molecule 
in serum [46]. Other medications including Alemtuzumab (Lemtrada) and Dacizumab 
(Zinbryta), both of which are monoclonal antibodies against CD52 or CD25 respectively, are 
also available to be used for the treatment of relapsing MS [47-49]. Therapies that reduce the 
trafficking of cells into the CNS are also used, in particular the oral therapy Fingolimod 
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(Gilenya) which reduces lymphocyte egress from lymph nodes by down-regulating 
sphingosine1-phosphate receptors (S1P) [50]. 
 
The most recent addition to the catalogue of MS DMTs is the anti-CD20 antibody ocrelizumab, 
which is the first and only drug approved by the US Food and Drug Administration (FDA) for 
the treatment of primary progressive MS. Ocrelizumab is a humanized monoclonal anti-CD20 
antibody which reduces B cells by antibody-dependent cell mediated cytotoxicity [51, 52]. 




1.2 Immunology of multiple sclerosis 
 CD4+ helper T cells in MS 
Studies in mouse models and MS patients suggest that inflammatory demyelination is primarily 
initiated by CD4+ T helper cells and maintained by pathogenic CD8+ effector T cells [1, 54]. 
In the mouse model of MS, experimental autoimmune encephalomyelitis (EAE), disease can 
be initiated by the passive transfer of myelin-specific CD4+ T cells alone, and effectively 
treated with anti-CD4 antibodies [55-57].  However, in a clinical trial long-term reduction of 
CD4+ T cell alone using anti-CD4 antibody showed no significant therapeutic effect [58]. The 
importance of CD4+ helper T cell is also suggested by the strong association with MHC class 
II, and many of the other genes implicated through genetic analysis, such as TAGAP and IL-
2RA. Furthermore the actions of the drugs which have been found to be effective, such as 
Natalizumab which particularly blocks the passage of CD4+ T cells into the CNS [59-61] and 
the established efficacy of Alemtuzumab further support the importance of T cells (both of 
CD4+ and CD8+ T) [62, 63]. 
 
 CD8+ T cells in MS 
As the genetic analysis of the MHC region has been refined in recent years it has become clear 
that the disease is also associated with MHC class I genes as well as class II genes, implicating 
CD8+ alongside CD4+ T cells [33, 64]. CD8+ T cells are a vital part of the effector arm of the 
adaptive immune system, that recognise antigen presented in combination with MHC class I, 
release proinflammatory cytokines, including interferon-gamma (IFN-γ) and tumour necrosis 
factor-alpha (TNF-α), and also give rise to a memory population. CD8+ T cells reactive to 
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myelin basic protein (MBP) have a pathogenic role in the development of EAE [65]. In MS 
lesions CD8+ T cells can be 10 times more frequent than CD4+ T cells [66-68], which is a 
higher ratio than in the blood [69, 70].  
 
 Th17 cells and Treg in MS 
In the last few years a new lineage of T helper cells distinct from the traditional Th1 (pro-
inflammatory) and Th2 (anti-inflammatory) lineages, and characterized by the production of 
IL-17 has been identified, called Th17 cells [71]. Studies in MS patients have shown an 
increased proportion of Th17 cells in CSF and blood during a relapse and increased expression 
of the Th17 cell specific transcription factors RORγt and RORα (encoded by the receptor-
related orphan receptor C gene; RORC) in peripheral blood mononuclear cells (PBMCs) from 
MS patients in comparison to healthy controls [72, 73]. In mouse models, the differentiation of 
naive T helper cells into Th17 cells has been shown to require IL-23 [74]. Deficiency in the 
expression of IL-23, or CCR7 (C-C chemokine receptor type 7), an essential ligand required 
for the production of IL-23 in dendritic cells (DC), causes a defect in the generation of Th17 
cells, and protects against the development of EAE [75, 76]. Evidence suggests that the Th17 
cell signature cytokine (IL-17A) also plays a pathogenic role as IL-17 knockout mice are 
significantly protected from EAE, and adoptive transfer of IL-17 deficient (-/-) CD4+ T cells 
does not efficiently induce EAE [77].  
 
Regulatory T cells (Treg) play a critical role in establishing peripheral tolerance and protecting 
against the development of autoimmune diseases and EAE [78-82]. FOXP3 is a key regulatory 
molecule in the maturation of Treg cells and genetic defects in the FOXP3 gene are known to 
cause dysregulation of immune homeostasis [83]. Also, inactivation or depletion of Tregs with 
anti-CD25 monoclonal antibody led to exacerbated EAE in mice [82]. In humans, there is no 
difference in the frequency of Treg cells in peripheral blood between healthy controls and MS 
patients, however, several studies have shown that the maturation of Tregs from patients are 
functionally impaired [84-86]. 
 
 NK and NKT cells in MS 
Natural killer (NK) cells have become attractive target for MS research in recent years. It is 
widely accepted that NK cells can be divided into cytotoxic ‘mature’ NK cells and cytokine 
secreting ‘immature’ NK cells, which can be phenotypically distinguished by the surface 
expression of CD56 and CD16 in human [87]. In vivo studies have shown that cytotoxic NK 
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cells are able to directly kill myelin-specific encephalitogenic T cells, and that depletion of NK 
cells causes an increase in the production of Th1 cytokines, which in turn promote the 
development of EAE [88, 89]. In MS patients, many studies have reported the dysfunction of 
the cytotoxic NK cell in the blood [90-93], while expansion of NK cells (using IL-2 antibody 
complex) suppressed inflammation in EAE through the inhibition of the Th17 pathway [94]. 
Notably, clinical studies have also shown that the DMT IFN-β upregulates immunoregulatory 
immature NK cells in the periphery blood and reduces cytotoxic mature NK cells [95-98]. 
 
NKT cells are a subset of T cells which are characterized by the recognition of the MHC class 
I-related protein CD1d [99]. NKT cells can be divided into invariant NKT cells (iNKT) and 
variant NKT cells dependent on the expression of a semi-invariant T cell receptor (TCR), which 
consists of Vα24-Jα18 and Vβ11 chains in human [99-101]. Activation of iNKT cells with 
alpha-galactocerebroside (α-GalCer) protects against the development of EAE in a manner that 
is dependent upon IL-4 and IFN-γ [102]. Moreover, IFN-β treated patients show an expansion 
of iNKT cells which enhances their regulatory effects [103]. Further investigation suggests that 
IFN-β exerts its effects on iNKT cells by altering the antigen-presenting capacity of dendritic 
cells (DCs) [103].  
 
 Cytokines and chemokines in MS 
The cytokine network is complex and several of the susceptibility loci identified in genetic 
studies map close to cytokine related genes [33]. Many studies have considered the effects of 
cytokines on the Th1 and Th17 pathways using transgenic knockout mice, recombinant 
proteins or antibodies; Table 1.1 below showed some key effects of cytokines in the mouse 
model EAE. 
 
The blood brain barrier (BBB) is formed by cerebral vessel endothelial cells, and functions to 
separate the circulating blood from the CNS. Dysregulation of chemokines or chemokine 
receptors can lead to the migration of T cells across the BBB into the CNS in MS [104]. It has 
been reported that CCR6 plays a critical role in the regulation of inflammatory T cell migration, 
and that mice deficient in CCR6 are resistant to the induction of EAE [105, 106]. Furthermore, 
increased expression of CCR5 and CXCR3 on T cells have been found in blood and CSF in 
MS patients [107]. Other chemokines identified that are dysregulated in MS include CCR1, 




Table 1. 1: The phenotypic effects of cytokines, cytokine receptors and transcription factors in 
EAE mouse models. (continued on next page) 
Cytokine KO mice/treatment Phenotype Reference 
IL-1 IL-1-/- Protected [109] 
 IL-1R-/- Protected [110] 
 IL-1α recombinant protein exacerbated [111] 
IL-2 IL-2-/- protected [112] 
IL-3 IL-3-/- protected [113] 
 IL-3 recombinant protein exacerbated [113] 
IL-4 IL-4-/- exacerbated [114] 
 IL-4-/- no phenotype [115] 
 IL-4Rα-/- protected [116] 
IL-6 IL-6-/- protected [117] 
 anti-IL-6 antibody protected [118] 
 anti-IL-6R antibody protected [119] 
IL-10 IL-10-/- exacerbated [120] 
 IL-10 transfection protected [121] 
IL-12 IL-12p35-/- exacerbated [122] 
 IL-12p40-/- protected [122] 
 IL-12Rβ1-/- protected [123] 
 IL-12Rβ2-/- no phenotype [123] 
 IL-12Rβ2-/- protected from remitting stage [124] 
 anti-IL-12 antibody protected [125] 
IL-17 IL-17-/- protected [77] 
 IL-17A-/- no phenotype [126] 
 Il-17F-/- no phenotype [126] 
IL-21 IL-21-/- protected [127] 
 IL-21-/- no phenotype [128] 
 IL-21R-/- protected [127] 
 IL-21R-/- no phenotype [128] 
IL-22 IL-22-/- no phenotype [129] 
IL-23 IL-23p19-/- protected [130] 
 IL-23R-/- protected [127] 
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IFN-γ anti-IFN-γ antibody exacerbated [131] 
 anti-IFN-γ antibody exacerbated [132] 
 IFN-γR-/- exacerbated [133] 
 IFN-γR-/- exacerbated [134] 
IFN-β recombinant IFN-β protected Th1-induced EAE [135] 
 recombinant IFN-β exacerbated Th17 induced EAE [135] 
 IFN-β-/- exacerbated [136] 
 IFN-β-/- exacerbated [137] 
TNFα TNFα-/- exacerbated [138] 
 TNFα-/- exacerbated [139] 
 anti-TNFα antibody protected in early stage [140] 
GM CSF CSF2-/- no phenotype [141] 
RORγt RORγt transfection exacerbated [142] 
T-bet T-bet transfection protected [142] 
 T-bet-/- protected [143] 
 
 
1.3 The genetic analysis of multiple sclerosis 
 Genome-wide studies 
Linkage analysis is a highly effective way of mapping disease loci in families affected by 
highly penetrant Mendelian disorders. However, the approach has little power in the analysis 
of complex diseases where susceptibility is determined by multiple loci each exerting only 
modest effects on risk [144]. In MS genome-wide searches for linkage have failed to find any 
significant evidence for linkage anywhere except in the MHC region (related to the long 
established DRB1*15:01 risk allele) [145]. On the other hand, genome-wide association 
studies (GWAS) in adequate sample sizes have high power to identify common susceptibility 
variants (those with a minor allele frequency of >5%) [146]. The approach relies on the 
extensive correlation that exists between the alleles of tightly linked common variants, linkage 
disequilibrium (LD) [147], which means that only a small fraction of common variation needs 
to be actually typed; these typed variants effectively “tag” the much larger number of un-typed 
variants [148]. International collaborative efforts such as the HapMap project have identified 
most common variants in the human genome (as listed in publicly available resources such as 
dbSNP: https://www.ncbi.nlm.nih.gov/projects/SNP/) [149]. It is now well recognised that 
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genotyping a few hundred thousand carefully selected common variants effectively enables 
more than 80% of common variation to be tested [150].  
 
The first GWAS for MS was completed by the International Multiple Sclerosis Genetics 
Consortium (IMSGC) in 2007 and considered 334,923 single nucleotide polymorphisms (SNPs) 
in 931 trio families (an affected individual and both their parents) in its screening phase [38]. 
In total three MS associated SNPs were identified two from the IL-2RA gene and one from the 
IL-7RA gene; these were the first non-MHC variants confirmed to be associated with the 
disease. Subsequently the IMSGC collaborated with the Wellcome Trust Case Control 
Consortium (WTCCC) and completed a significantly more powerful GWAS which was 
published in 2011 and included 9,772 cases and 17,736 controls tested at 465,434 SNPs in the 
screening phase [33]. This study brought the total number of non-MHC associated variants to 
57. Following this the IMSGC fine mapped 184 genomic regions in 14,498 cases and 24,091 
controls using the ImmunoChip, and extended the number of associated non-MHC variants to 
110, each with genome-wide significant evidence for association (p<5x10-8) [151]. Table 1.2 
shows a summary of GWAS efforts in MS. Since completing the ImmunoChip analysis the 
IMSGC has performed a meta-analysis of MS GWAS and genotyped potentially associated 
variants on a custom “MSchip”, a pre-print of this work has been published in Biorxiv and lists 
a total of 201 non-MHC associated variants [37], which together with the MHC account for 
about a 20% of the heritability of MS.  
 
It is striking that nearly all the MS associated genetic variants are located in regulatory non-
coding regions of the genome in or near to genes with known immunological functions [33, 
151]. These data provide some of the strongest evidence supporting the importance of 
immunological processes in the aetiology of MS. However, because of the extensive LD 
between common variants, each of the associated SNPs implicates a genomic region rather 
than just the nearest gene. Thus, it is challenging to establish which specific genes and 
functional pathways are implicated by these associations.  
 
 The association of chromosome of 14q31.3 and MS 
One of the most strongly associated SNPs identified in the 2011 GWAS was rs2119704 
(p=2.2x10-10) from chromosome 14q31.3 [33]. The region implicated by this SNP was also 
included in the ImmunoChip study, which enabled detailed fine mapping of the association that 
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identified rs74796499 (p=8.47x10-11; r2 = 0.6; D’ = 0.993) as the lead most associated SNP in 
the region (Figure 1.1) [151]. Both the GWAS and ImmunoChip lead variants have a low minor 
allele frequency (MAF), 6% for rs2119704 and 3% for rs74796499 in the UK ImmunoChip 
data, with the minor allele being protective in each case. Within this associated region, there 
are two protein coding genes: galactosylceramidase (GALC) and G protein coupled receptor 65 
(GPR65, also referred to as T cell death associated gene 8, TDAG8), and a long intergenic non-
coding RNA gene LINC01146, the function of which is unknown [152]. Both GALC and 
GPR65 have functions that make them logical and promising candidate genes in MS. 
 
The associated variants in the region containing these two coding protein genes are in tight LD, 
making it difficult genetically to determine which gene is associated with the MS susceptibility 
SNP. The SNP rs2119704 lies downstream of GPR65, whilst rs74796499 lies within intron 8 
of GALC (Figure 1.1).  
 
Table 1. 2: Completed GWAS for MS listed on GWAS catalogue and the latest IMSGC papers. 
(continued on next page)  
Year Study Tested 
SNPs 
Sample size Identified 
SNPs 
2007 Risk alleles for multiple sclerosis identified 
by a genome-wide study [38]. 
335k 931 trio 
families 
6 
2009 Genome-wide association analysis of 
susceptibility and clinical phenotype in 
multiple sclerosis [153]. 
552k 883 controls 
978 case 
11 
2009 Meta-analysis of genome scans and 
replication identify CD6, IRF8 and 
TNFRSF1A as new multiple sclerosis 
susceptibility loci [153]. 
2.56m 7220 controls 
2624 cases 
16 
2009 Genome-wide association study identifies 
new multiple sclerosis susceptibility loci on 
chromosomes 12 and 20 [154]. 
302k 3413 controls 
1618 cases 
9 
2010 Genome-wide association study in a high-
risk isolate for multiple sclerosis reveals 
associated variants in STAT3 gene [155]. 





2010 Variants within the immunoregulatory 
CBLB gene are associated with multiple 
Sclerosis [156]. 
6.6m 872 controls 
882 cases 
2 
2011 Genome-wide meta-analysis identifies 






2011 Genetic risk and a primary role for cell-
mediated immune mechanisms in multiple 





2013 Analysis of immune-related loci identifies 







2013 Fine-mapping the genetic association of the 
major histocompatibility complex in 
multiple sclerosis: HLA and non-HLA 
effects 
3613 9595 controls 
5091 cases 
11 
2016 Novel multiple sclerosis susceptibility loci 








Figure 1. 1: Manhattan plot for the fine mapped region on chromosome 14q31.3 in the 
ImmunoChip study. The negative log p value of each SNP is plotted against the position on the 
chromosome. The horizontal dash lines indicate the GWAS significance threshold (-log (p) = 
7.3) and the a priori discovery threshold in the ImmunoChip study (-log (p) = 4). Grey indicates 
–log (p) ≥ 4, yellow indicates –log (p) ≥ 4 and <7.3, while red indicates –log (p) ≤7.3. Full 
details can be found in ImmunoBase [151]. The figure was generated with help from my 














 The role of GALC in myelin metabolism 
The GALC gene encodes the lysosomal enzyme β-galactosylceramidase, which plays an 
important role in the hydrolysis of specific galactolipids, including the otherwise non-
degradable galactosylceramide (GalC) and galactosylsphingosine (psychosine) [159]. In the 
homozygous or compound heterozygous state, mutations in GALC that result in loss of function 
in β-galactosylceramidase lead to the development of Krabbe disease (also known as globoid-
cell leukodystrophy, an autosomal recessive inherited neurodegenerative disorder) [160, 161]. 
More than 70 GALC gene mutations have been found in relation to the development of Krabbe 
disease. The crystal structure of GALC reveals that all parts of the protein contribute to the 
substrate binding site, which explains why the mutations causing Krabbe Disease are widely 
distributed across the gene [162]. 
 
GalC and its sulphate derivatives are essential components of the myelin produced by 
oligodendrocytes in the CNS [163] and lack of GalC in mice has been shown to alter 
oligodendrocyte maturation [164]. Psychosine, one of the potential breakdown products of 
myelin, is highly neurotoxic and has lethal effects [165]. Removal of psychosine is almost 
entirely dependent upon GALC such that this metabolite accumulates in patients with Krabbe 
disease and causes demyelination due to apoptosis of oligodendrocytes [166, 167]. This results 
from down-regulation of lipopolysaccharide (LPS) induced NF-kB and up-regulation of a pro-
apoptotic AP-1 pathway by psychosine [168]. Many studies in the twitcher mouse model, a 
natural model of Krabbe disease, have shown psychosine induced apoptosis on glial cells and 
fibroblasts as well, however, only low level apoptotic cell death is seen in human lymphocytes 
[169-171]. On the other hand, a recent study found that the high psychosine concentration 
caused by GALC functional defects in the brainstem and spinal cord does not correlate with 
white matter loss or gliosis, suggesting that psychosine levels may not be the only factor 
responsible for demyelination [172]. 
 
 The role of GALC in the immune system 
Increased levels of proinflammatory cytokines and chemokines have been found in the CNS in 
Krabbe disease including increased levels of TNF-α, MIP-1β, MCP-1 and CD68 [173]. 
Furthermore, D-galactosyl-β1-1’-sphingosine (psychosine) and D-glucosyl-β1-1’-sphingosine, 
but not other lipids, are reported to induce chemotaxis and apoptosis of human NK cells in 
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vitro [174]. Also, both these glycosphingolipids have been shown to bind TDAG8 (GPR65) in 
mice. These results suggest a functional defect in GALC may alter GPR65 activity as a result 
of the accumulation of these particular glycosphingolipids, leading to an altered immune 
response.  
 
A recent study investigating PBMCs from Krabbe patients found a low concentration (5 µM) 
of psychosine contributes to proinflammatory activation through increased TNF-α secretion, 
but that TNF-α was not affected at a higher concentration (20 µM) of psychosine [175]. These 
results suggest that in Krabbe disease, there is a proinflammatory activation of the immune 
system as well as psychosine induced glial cells apoptosis. In the twitcher mouse model 
elevated levels of IL-6 and TNF-α are seen in the CNS [176]. Interestingly, the IL-6 deficient 
mice also showed more severe Krabbe disease due to the damage or disruption of the blood-
brain barrier, allowing T cells to cross over and attack myelin [177]. Disruption of the blood-
brain barrier is one of the hallmarks of MS, and the role of GALC in this process needs to be 
explored further [178]. 
 
 GALC and MS 
Both Krabbe disease and MS are demyelinating diseases, however in MS the demyelination is 
a consequence of an autoimmune attack on myelin (see Chapter 1.1), while in Krabbe disease 
it is caused by the accumulation of toxic galactosylsphingolipid. There is no evidence to 
suggest that heterozygous carriers of Krabbe disease variants are at higher risk of developing 
MS. 
 
Neither of the MS associated SNPs rs2119704 and rs74796499 are associated with Krabbe 
disease or any other complex trait. However, this region of the genome has also been linked to 
both Crohn’s disease and ankylosing spondylosis (AS); the Crohn’s disease associated variant 
rs8005161 (p=1.3x10-8) [179] and the AS associated variant rs11624293 (p=1.5x10-10) [180] 
being in complete LD (r2=1.0) with each other, i.e. being perfect proxies for each other. This 
Crohn’s disease/AS associated variant is not associated with MS, suggesting independent 





 The function of GPR65 
GPR65, a G protein couple receptor (GPCR), is a membrane protein containing 337 amino 
acids with a molecular mass of 39kD. It is predominantly found in lymph nodes, thymus and 
lymphoid tissues, including peripheral blood leukocytes [152, 181]. GPR65 was first identified 
to be a gene through increased mRNA expression during T cell activation and thymocyte 
apoptosis with the treatment of anti-TCR (T cell receptor) antibody or glucocorticoid [181]. 
This study suggested that GPR65 may be involved in T cell apoptosis and thereby negative 
selection of immature thymocytes. However, another study showed that GPR65 knockout mice 
had normal glucocorticoid induced thymocyte apoptosis [182]. 
 
Several studies have demonstrated that activation of GPR65 increases the intracellular second 
messenger cAMP (cyclic adenosine 5’-monophosphate) concentration and leads to triggering 
of the PKA (protein kinase A) signalling pathway [183-185]. In T cells, one the main effects 
of cAMP is to activate PKA, which disrupts lipid rafts in the plasma membrane and is thereby 
a negative regulator of T cell function [186-188]. A functional study showed cAMP induced 
PKA activity negatively regulates proximal TCR signalling by phosphorylation of tyrosine-
protein kinase Csk (C-terminal Src kinase) and co-localizing with the TCR complex [189].  
Elevation of cAMP also activates the transcription factor CREB (cAMP response element 
binding protein), leading to upregulation of cytokine expression including the anti-
inflammatory cytokine IL-10 [190]. Recent studies also showed that activation of CREB by 
cAMP regulates FoxP3 expression to maintain the Treg phenotype [191, 192]. Furthermore, 
activation of GPR65 using a synthetic agonist BTB09089 has been shown to increase 
intracellular cAMP and thereby reduce production of IL-2, TNF-α and IL-6 [193]. Collectively, 
these studies suggest that activation of GPR65 regulates inflammatory cell activity, particular 
T cells and their cytokine production, through the cAMP/PKA pathway.  
 
In addition in a cancer cell line investigators found a functional role for GPR65 in apoptosis in 
an acidic environment, with GPR65 upregulating anti-apoptotic bcl-2 in a manner dependent 
on mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK/ERK) 
signalling pathway but independent of cAMP induced PKA [194]. In addition to cAMP/PKA 
and MEK/ERK pathways, GPR65 was also reported to be involved in actin reorganization 
through Gα12/13 dependent activation of Rho [195].  
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 Function of GPR65 in acidic microenvironment 
GPR65, GPR4, OGR1 (GPR68) and G2A (GPR132) are all proton sensing receptors. At an 
acidic pH, proton transfer to the histidine residues in the first loop of GPR65 leads to a 
conformational change which alters function [196]. Mutations at amino acids 10, 14 or 243 (all 
histidine residues) have been shown to reduce the production of cAMP in acidic 
microenvironments and inhibits the proton-sensing response in an in vitro study. In mice the 
peak activation of GPR65 occurs when the extracellular environment is between pH 6.5 to pH 
7.0 [181, 183]. Acidic microenvironments have been shown to increase the viability of 
eosinophils [185] and inhibit the production of proinflammatory cytokines including TNF-α in 
a cAMP and GPR65 dependent manner [197].  
 
Given that inflammatory lesions are locally acidic the activation of GPR65 in acidic 
environments and its role in modulating immune function could have particular relevance in 
autoimmune diseases like MS [198]. Investigations in cancer, where the microenvironment 
within tumors is frequently acidic, have shown that GPR65 activity influences the development 
and growth of tumors. Overexpression of GPR65 in mouse lewis lung carcinoma cells 
promotes growth and resistance to acidification induced cell death by cAMP/PKA and ERK 
related pathways in vitro [199]. Similarly knockdown of GPR65 in NCl-H460 human non-
small cell lung cancer cells reduce the cells viability in an acidic environment [199]. On the 
other hand, GPR65 has also been reported to act as a tumor suppressor by reducing the 
expression of c-Myc oncogene in human lymphoma cells under acidosis [200], and expression 
of GPR65 mRNA is decreased by 50% in human lymphoma samples in comparison to non-
tumor lymphoid tissues [200]. 
 
 GPR65 is a psychosine receptor 
Interestingly it has been shown that psychosine and several related glycosphingolipids, 
including Lac-psychosine and lysosulfatide, are ligands for GPR65 [201]. However, the data 
regarding how these moieties affect GPR65 and consequently immune function is inconsistent. 
In a GPR65 transgenic mouse activation of GPR65 with psychosine was shown to inhibit 
glucocorticoid induced cytokine production [201, 202]. However, other investigators saw no 
effect of psychosine on the immune system or glucocorticoid induced thymocyte apoptosis 
[182]. It has also been shown that the inhibitory effects of GPR65 induced by acidity can be 




 GPR65 and autoimmune diseases 
Few studies have examined the function and expression of GPR65 in humans, but as described 
in Chapter 1.3, genetic variants in the region of GPR65 are associated with MS [33], Crohn’s 
disease [179, 203] and ankylosing spondylitis [180]. In mice the gene has been suggested to 
play a role in T cell mediated disease [152] and GPR65 knockout mice show an enhanced 
tendency to develop anti-collagen type II antibody induced arthritis [193, 204, 205]. In addition, 
more severe induced adoptive transfer of delayed type hypersensitivity to methylated bovine 
serum albumin (BSA) has been observed in GPR65 deficient transferred mice, but not in 
GPR65 deficient recipient mice [206]. Finally, knocking down GPR65 or carrying the GPR65 
Crohn’s disease risk allele has been suggested to lead to increased lysosomal pH, resulting in 
impaired clearance of intracellular bacteria and accumulation of aberrant lysosomes [203]. In 
vitro, naive GPR65 deficient T cells differentiated 40% fewer IL-17A-producing cells, with a 
similar reduction observed in IL-23 treated memory cells. In the absence of GPR65 in T cells, 
mice are protected from EAE [207]. Furthermore, ChIP-Seq analysis indicated RORγt, the 
master transcription factor for Th17 cells, binds the promoter region of GPR65 [208]. These 
data all suggest that GPR65 may influence the development of MS by altering Th17 cells. 
 
 
1.6 Preliminary assessment of GALC and GPR65 
In a pilot study my predecessor in the lab, Dr Tom Button, investigated the relationship between 
T cell activation and genotype at the MS associated SNP (rs2119704) at varying pH (7.0 - 7.4); 
the results of which are shown in Fig 1.2. His results suggested that rs2119704 genotype 
influenced T cell activation at pH levels below the normal physiological level. Given the known 
acid sensing function of GPR65 it seemed reasonable to hypothesize that genotype dependent 
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Figure 1. 2: Lymphocyte activation at varying pH in wild type homozygote and heterozygote 
individuals. Activation is measured after anti CD3/CD28 stimulation in terms of the % of CD25 
positivity.  Carriers of the protective allele (n = 5) and non-carriers (n = 9) are compared at the 




Although the genetic analysis of multiple sclerosis has identified over two hundred associated 
variants little is known about how these exert their effects on risk and result in the development 
of the disease. The association with rs74796499 on chromosome 14q31.3 implicates two 
interesting genes GALC and GPR65, both of which have the potential to be relevant in the 
pathogenesis of MS. The LD flanking the minor protective allele at rs74796499 implicates a 
range of variants over the region containing these genes, including a synonymous splice region 
variant in GALC (rs11552556). Other independent haplotypes in the region are associated with 
susceptibility to Crohn’s disease and AS but the haplotype containing the minor allele at 
rs74796499 appears to exert an MS specific effect. Based on the preliminary results observed 
by my predecessor Dr Tom Button I decided to focus my efforts to understand this association 
on GPR65, as this acid sensing receptor seemed more likely to underlie an acid specific 
genotype dependent effect. It seemed to me that GALC was less likely to be relevant since 
there is no evidence that any of the loss of function mutations underlying Krabbe disease have 






Chapter 2: Materials and Methods 
My research was approved by the South Central – Berkshire National Research Ethics Service 
(NRES) Committee (study reference number 15/SC/0087) and all study subjects gave fully 
informed written consent. The experimental procedures I used in my research are detailed 
below. 
 
 Human PBMC isolation and cell separation 
Venous blood from healthy human individuals was collected in heparin tubes (Sarstedt, 
Germany) by research nurses and transferred to the lab where peripheral blood mononuclear 
cells (PBMCs) were isolated using Ficoll-Paque (GE Healthcare, UK) density gradient 
centrifugation. Collected cells were then washed twice in sterile phosphate-buffered saline 
(PBS) solution and counted using a Brightline haemocytometer (Hausser Scientific, US), with 
viability assessed using trypan blue dye exclusion (Sigma, UK).  
 
Mononuclear cells were then suspended in magnetic activated cell sorting (MACS) buffer and 
positively separated using either CD56+ MACS MicroBeads and/or CD3+ MicroBeads 
(Miltenyi Biotec, UK) to isolated NK/NKT cells and T/NKT cells respectively. Cell separation 
was completed using the autoMACS Pro Separator (Miltenyi Biotec, UK) according to the 
manufacturer’s protocol. For each subject, the remaining cells (CD56- and CD3- cells) and an 
aliquot of the separated T cells and NK cells (up to 1.5x 107 cells of each) were rapidly 
resuspended in 1 mL TRIzol reagent (Ambion, US) and stored at -80°C prior to DNA and RNA 
extraction. 
 
 Immunocytochemistry (ICC) 
Freshly isolated human PBMCs were isolated by autoMACS Pro Separator into three groups: 
T cells (CD3+); NK cells (CD3- CD56+) and the remaining fraction a B cells and monocytes 
enriched population (CD3- CD56-) and fixed with 4% paraformaldehyde (PFA) for 15 min and 
then washed twice with PBS. Cells were then spread on a polysine-coated microscope slide 
and dried for 2 hours at room temperature followed by blocking with ICC blocking buffer for 
an hour at room temperature. Sections were then immune-labelled using rabbit anti-GPR65 
antibody diluted 1 in 100 followed by the Alex Fluor 647 labelled polyclonal donkey anti-
rabbit antibody (1 in 1000 dilution) provided by Prof Robin Franklin group. Cells were also 
stained with DAPI (4', 6-diamidino-2-phenylindole), a fluorescent stain, that selectively binds 
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nuclei with limited background of cytoplasm. Sections were coverslip mounted and imaged 
using an Axio Observer inverted microscope (Zeiss, Germany) at a magnification of x20. 
 
 Pierce bicinchoninic acid (BCA) protein assay 
Protein concentration was determined using the Pierce BCA protein assay kit (Thermo Fisher, 
UK) completed according to the manufacturer’s protocol. Unknown concentrations were 
determined using a plate specific standard curve created by serially diluting (1 in 2 dilution) a 
2 µg/µL standard down to 15.625 ng/µL. Standards and samples were processed on a 96-well 
plate and gently shaken to mix reagents. The plate was incubated at 37°C for 30 min, then read 
on a micro plate reader (Bio-Rad). The average blank-corrected 562nm absorbance 
measurement of each serially diluted sample was used to create a standard curve. The 
concentration of unknown technically triplicated samples was calculated using the standard 
curve method. 
 
 Western blot 
For each sample a total of 5x106 cells were washed in PBS and centrifuged for 10 min at 300g. 
Cells were lysed on ice with cell lysis buffer followed by sonication. 20 or 30 µg protein from 
each sample and 10 µL prestained protein ladder (Bio-Rad, UK) were loaded onto a NuPAGE 
Novex Bis-Tris gel (Thermo Fisher, UK). Protein was transferred to a polyvinylidene 
difluoride (PVDF) membrane at 30V for 1 hour using the XCell Blot Module followed by 
blocking the membrane in 5% (w/v) non-fat dry milk in PBS-T for 1 hour at room temperature. 
The membrane was incubated with primary antibodies overnight at 4°C with gentle shaking. 
The membrane was then washed with PBS-T three times followed by incubation with or 
without Horseradish peroxidase (HRP) conjugated secondary antibodies (Dako, Glostrup 
Denmark) for 2 hours. The bound antibodies were detected by using HRP substrate ECL plus 
detection reagent (GE Healthcare, UK) and visualised using the ChemiDoc XRS+ Systems 
(Bio-Rad, UK). Protein expression was normalized to the loading control protein using Imagine 
J (version 1.49) analysis software. 
 
Protein dephosphorylation 
Dephosphorylation of tyrosine, threonine and serine residues in sample proteins was achieved 
by incubating protein lysate with Lambda protein phosphatase (New England Biolabs, UK) for 
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2 hours at 30°C. The enzyme was then inactivated by heating with Na2EDTA for 1 hour at 
65°C. Samples were then assessed by Western blot with anti-GPR65 antibody. 
 
Protein deglycosylation 
To remove cross-linked glycans, the protein deglycosylation mix kit (New England Biolabs, 
UK) was used under denaturing and non-denaturing conditions. For denaturing conditions 100 
µg of sample protein was mixed to 10x glycoprotein denaturing buffer followed by heated to 
100°C for 10 min and cooled down prior to the addition 10x glycoprotein denaturing buffer 
and deglycosylation enzyme cocktail. For non-denaturing condition, 100 µg of sample protein 
was directly mixed with deglycosylation enzyme cocktail gently. Both reactions were 
incubated at 37°C for 4 hours. The deglycosylated reactions were assessed by Western blot 
with the same GPR65 antibody used as described above. 
 
 Protein complex immunoprecipitation (Co-IP) and Mass Spectrometry 
analysis 
Co-IP 
In order to undertake Co-IP 10 μg of commercial GPR65 specific antibody were firstly 
combined with 1.5 mg of Pierce protein A/G magnetic beads (Thermo Fisher, UK). The 
mixture was washed with binding/wash buffer and Dynabeads labelled antibody collected with 
a magnetic stand. The Dynabeads labelled antibody was then added to protein lysates and the 
resulting precipitates collected. Elution buffer was added and incubated for 2 min with rotation 
to dissociate the Dynabeads from complexes. The Dynabeads were then removed from the 
antibody protein complexes using a magnetic stand.  
 
Coomassie staining 
Coomassie brilliant blue R-250 (Sigma, UK) was used to stain protein samples after 
electrophoretic separation in a Bis-Tris gel. The gel was incubated in 0.1% coomassie staining 
buffer for 1 hour in a sealable container with gentle shaking at room temperature. The gel was 
then washed and incubated in a de-staining buffer for 4 hours to remove excess staining buffer.  
 
Mass spectrometer 
The mass spectrometry analysis was performed by Cambridge Centre for Proteomics. The 
sample peptides were separated by high-resolution nanoscale chromatography. The mass 
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accuracy tandem mass spectra (MS/MS) were then acquired automatically. The results were 
then compared against all the entries in the latest NCBI database (Release number 211) to 
generate Mascot histograms.  
 
 siRNA transfection 
GPR65 knockdown was attempted using the human T cell Nucleofector kit (Amaxa Lonza, 
USA). Specially, in each experiment 100 µL of transfection reagent was used to process 1x107 
freshly separated PBMCs. 
 
To test the efficiency of the knockdown in human T cells, initial experiments were completed 
using a positive control pmax green fluorescent protein (pmaxGFP) vector to test the 
nucleofector programs. Cells were transfected using 2 nM pmaxGFP, and processed using 
electroporation programs U-014 or V-024 on a Nucleofector 2b device. Cells were then 
incubated in DMEM for 5 hours at 37°C in 5% CO2, harvested and incubated again with anti-
CD3 plus anti-CD28 antibodies for a further 18 hours. Flow cytometry was used to detect the 
expression of GFP. The efficiency of knockdown was expressed as the percentage of GFP 
expressing T cells. 
 
 DMEM pH measurement and adjustment 
Dulbecco’s Modified Eagle Medium (DMEM) was adjusted to the required pH (ranging from 
pH 6.2 to pH 7.6) with sodium bicarbonate (Sigma, UK) prior to cell culture in a 5% CO2 
humidified environment. The mass of bicarbonate needed to adjust the DMEM to the desired 
pH was calculated according to the Hendersion-Hasselach equation. Osmolality was balanced 
using sodium chloride (Sigma, UK). The pH pre-adjusted DMEM was then filtered with a 0.22 
micron filter (Merck Millipore, Germany) and stored in a sterile environment at 4°C. To ensure 
the pH of the medium was maintained and consistent, the pH was pre-checked after incubation 
overnight with or without cells prior to use in the experiment. The pH value at 37°C were 




pH = 6.1 + log (52 ×





 Cell culture 
All cell cultures were undertaken in pre-made DMEM at 37°C in a humidified atmosphere 
containing 5% CO2. In initial experiments designed to establish the conditions required to 
ensure stable extracellular pH throughout the period of culture, different cell numbers (0.5 or 
1 x 106), culture plates (48-well or 96-well flat bottom plates, Nuclon, US), culture volumes 
(0.5 mL or 0.2 ml) and cell cultured medium (DEME or RPMI) were tested. Stimulation was 
performed using plate bound anti-CD3 and soluble anti-CD28 antibodies (Affymetrix 
eBioscience, US) at a final concentration of 1 µg/mL, or with Dynabeads™ Human T-Activator 
CD3/CD28 (Gibco by Life Technologies, US) at the same final concentration. To establish the 
length of culture needed to reach maximal T lymphocyte activation, the expression of CD25 
and CD69 was measured at 6, 24, 32, 48, 56 and 72 hours following activation with plate bound 
anti-CD3/CD28 antibodies, at differing pH values. 
 
T cell activation 
Anti-CD3 antibody was incubated in 48-well flat bottom plates for 2 hours at the concentration 
of 1 µg/mL. Plates were then washed with PBS twice to remove unbound antibodies. The 
soluble anti-CD28 antibodies were added in and used to stimulate 1x106 PBMCs at final 
concentration of 1 µg/mL. Cells were then incubated for 18 hours for full T cell activation.  
 
GPR65 functional assay 
Previous studies have shown the synthetic molecule BTB09089 (Maybridge, UK) is a specific 
agonist of GPR65. Dimethyl sulfoxide (DMSO) was used to solubilise BTB09089. To 
investigate the impact of DMSO on T cell subtypes and T cell activation, a DMSO 
concentration titration experiment (ranging from 0 µM to 50 µM) was performed and 
proportion of T cell subtypes and T cell activation measured by flow cytometry. To determine 
the specific action of GPR65, 1x106 PBMCs were seeded onto an anti-CD3 coated plus soluble 
anti-CD28 48-well culture plate with DMEM at pH 6.2, pH 7.0 and pH 7.6 containing 20 μM 
BTB09089 and incubated for 18 hours. Activation of T cells, NKT cells and NK cells were 
measured by CD25 and/or CD69 expression using flow cytometry.  
 
 Flow cytometry 
Cells were collected and washed twice in PBS. Fixable viability dye (eBioscience, US) were 
used for live/dead staining, diluted with PBS to a concentration of 1 µg/mL and incubated with 
34 
 
cells for 30 min. Cells were then washed twice with PBS and transferred to 96-well U-shape 
bottom plates (Corning, US). Cells were blocked with FACS buffer containing 2% mouse 
serum for 15 min, and labelled with fluorescent conjugated antibodies by incubating for 20 min 
at 4°C. The panel of fluorochrome antibodies used in each experiment is described in the 
respective chapters. Each antibody was titrated to determine the optimal concentration for flow 
cytometry. Annexin V Apoptosis Detection kit (eBioscience, UK) was used for labelling early 
apoptotic cell. Cells were washed with binding buffer and incubated with fluorochrome-
conjugated Annexin V diluted with binding buffer at a concentration of 50 μg/mL for 15 min 
at room temperature. The binding buffer were then used to wash and remove the excess 
Annexin V. Cell fixation was performed with 100 µL 2% PFA incubated for 20 min at 4°C. 
Compensation matrices were created using single-stained cells or anti-mouse compensation 
particles (BD Bioscience, US) for each fluorochrome. Cells were then resuspended in 500 µL 
of FACS buffer for flow cytometry analysis. All flow cytometry was performed on the Fortessa 
II (BD Bioscience, US) and a total of 20,000 gated lymphocytes were recorded.   
 
 Flow cytometry gating strategy 
The flow cytometry data were analysed using FlowJo software (version 10). Unstained controls 
were used to define negative gates (thresholds), except for the work described in Chapter 8 
when fluorescence minus one (FMO) controls were used to define the LacCer and CD69 
thresholds. In initial experiments I performed I found no significant difference using unstained 





Figure 2. 1: Example analysis of human PBMC. A, FSC/SSC (lymphocyte gate). B, SCW/FSC 







CD56- cells, NKT cells, NK cells). E, FSC/CD4-BUV395 in T cells (CD4+ T cells). F, 
FSC/CD8-APC in T cells (CD8+ T cells). G, FSC/CD8-APC in NKT cells (CD8+ NKT cells). 
H, FSC/CD19-BUV737 in CD3- CD56- cells (B cells). 
 
 
Figure 2. 2: Example of LacCer and CD69 negative gates in human cultured T cells. A total of 
20,000 lymphocytes were collected and analysed as described above. LacCer and CD69 







LacCer (CD17) CD69 
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 Lysosomal pH measurement 
The LysoSensor Green DND-189 dye (Invitrogen, US) was used to measure intracellular pH. 
For this T cells (CD3+), monocytes (CD14+), B cells (CD19+ CD3- CD56-) NKT cells (CD3+ 
CD56+) and NK cells (CD3- CD56+) were labelled using appropriate antibodies then 
incubated with 1 µM LysoSensor Dye for exactly 5 min. After two washes with FACS buffer, 
the mean fluorescence intensity (MFI) was measured by flow cytometry and analysed by 
FlowJo software (version 10). Values were normalised against the antibodies bound to 
Compbeads (BD Bioscience, US) which were used as a positive control for each experiment. 
The incubation time and the dye concentration were optimized in initial experiment set up 
described in Chapter 7.2. 
 
 DNA/RNA extraction 
Trizol was used for DNA/RNA extraction following the manufacture’s protocol. Trizol stored 
samples were allowed to defrost to room temperature for 5 min to permit completely 
dissociation of the nucleoprotein complex. 200 µL chloroform was added in each homogenized 
sample followed by shaking and centrifugation to separate the mixture into a lower red phenol-
chloroform phase, a DNA contained interphase and a colourless RNA contained upper aqueous 
phase.  
 
RNA isolation  
The RNA contained aqueous phase was transferred to a new eppendorf and mixed with 500 µL 
isopropanol and then incubated on ice for 30 min. Samples were then centrifuged at 12,000 g 
for 15 min at 4°C to precipitate RNA as a pellet. After washing with 1 mL 75% ethanol and 
air-drying for 5 min, RNA was then resuspended in RNase-free water at 55°C – 60°C. The 
concentration of RNA was measured using spectrophotometry. 
 
DNA isolation 
The phenol-chloroform phase and the DNA contained interphase were mixed with 100% 
ethanol by gentle shaking. Normally the DNA pellets became visible. Samples were then 
centrifuged and organic phenol-chloroform phase stored at -80°C for protein analysis. The 
DNA pellets were then washed twice with 0.1 M sodium citrate buffer then stored in 75% 





DNA and RNA concentration were measured and calculated from the absorbance at 260 nm 
using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific, US).  
 
 DNase treatment and clean-up 
DNase I (Invitrogen, UK) was used to remove any contaminating genomic DNA (gDNA) from 
the RNA samples. One unit of DNase I enzyme was used for each 1 µg RNA with the 
proprietary reaction buffer, the mixture being incubated for 30 min at 37°C. The same amount 
of 50 mM EDTA (Ethylenediaminetetraacetic acid) was added as an exonuclease inhibitor and 
incubated for 15 min at 65°C to terminate the reaction. DNase I treated sample was purified 
and concentrated using RNeasy MinElute Cleanup kit (Qiagen, Germany) according to the 
manufacturer’s instructions. RNA was eluted in RNase/DNase free water.  
 
 Bioanalyzer for RNA integrity number 
RNA quality was examined by capillary electrophoresis using the Agilent 2100 Bioanalyzer 
system (Agilent Technologies, US) according to the manufacturer’s protocol. The RNA 
integrity number (RIN), an algorithm for assigning the RNA integrity, was automatically 
calculated and generated within Agilent 2100 Expert software (Agilent Technologies, US) 
[209]. RIN values range from 1 to 10, with 10 being the highest quality of RNA. In general, 
the electropherogram for a typical sample shows a small 5S peak, a larger 18S peak and a 28S 
peak (Figure 2.3). As 28S ribosomal RNA (rRNA) tends to be degraded more quickly than 18S 








Figure 2. 3: An example of the Bioanalyzer electropherogram and computer modelled gel plots. 
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degradation of rRNA. An aliquot of 2 µL RNA were taken for concentration measurement and 
Quality control. All samples analysed had a RIN > 8.0.  
 
 cDNA synthesis 
I used the SuperScript™ III First-Strand Synthesis System (ThermoFisher, US) which contains 
SuperScript III reverse transcriptase, Oligo-dT and random hexamers to synthesise cDNA in 
accordance with the manufacturer’s instructions. In this 1 µg of cleaned-up RNA was mixed 
with the cDNA synthesis kit regents (Table 2.1) and processed according to the manufacturer’s 
instruction (see Table 2.2 for more details). Samples were finally collected and chilled in an 
ice block then stored at -20°C.  
 
Table 2. 1: cDNA synthesis reagent mixture 
 Components Volume for each reaction 
Mixture A   
 10 mM dNTP mix 1 µL 
 50 µM oligo (dT) 0.5 µL 
 Random Hexamer 0.5 µL 
 RNase free water Top up to 13 µL 
   
Mixture B   
 5x First Strand Buffer 4 µL 
 0.1 M DTT 1 µL 
 RNaseOUT (40 U/ µL) 1 µL 
 SuperScript III RT (200 U/ µL) 1 µL 
 
 
Table 2. 2: cDNA Reverse Transcription Kit Reagents and thermal cycle program. 
Step Temperature Time Reagents for each reaction 
1 65°C 5 min Mixture A and RNA sample 
2 25°C 60 min Added Mixture B 
3 50°C 10 min  
4 70°C 15 min  
storage -20°C ∞  
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 quantitative PCR 
Gene expression was assessed by quantitative PCR (qPCR) of cDNA from either ex-vivo NK 
(CD56+) /non-NK cells or T (CD3+) /non-T cells. These reactions were performed in 384 well-
plates, with each reaction containing 2 µL cDNA, 20x pre-designed primers (Table 2.3), 2x 
Universal Master Mix (Life Technologies, US) made up to 10 µl with DNase/RNase free water. 
The relative abundance of cDNA was determined in triplicate by qPCR analysis using the 
QuantStudio 7 Flex system (Applied Biosystems, US) and standard Taqman program (Table 
2.4). Each gene was normalized to the housekeeping gene β-ACTIN prior to calculation of the 
relative expression in order to correct for variation in cDNA concentrations. 
 
Quantification of the expression of target genes 
The relative standard method was used to calculate and compare the target gene expression. 
The standard curve is generated by qPCR of a 5 folds serial dilution of a stock cDNA with the 
Ct (cycle threshold) determined for each dilution. The quantity of target genes and 
housekeeping gene β-ACTIN (endogenous control) were calculated by interpolating from the 
standard curve followed by normalization to their housekeeping gene (see equation below). 
The normalized target genes were compared by genotypes. 
 
The relative gene expression: 






Table 2. 3: qPCR primers 
Primer Amplicon (bp) Hs assay code Vender 
β-ACTIN 171 Hs99999903 Life Technologies 
CD69 94 Hs00156399 Life Technologies 
GALC 82 Hs01012300 Life Technologies 
GPR65 86 Hs01087326 Life Technologies 
GPR65 124 Hs00269247 Life Technologies 
RORC 62 Hs01076112 Life Technologies 




Table 2. 4: qPCR program 
Step Temperature Time Cycles 
Initial denaturation 95°C 10 min  
Denaturation 95°C 15 sec Repeat these 2 steps 
for 40 cycles Annealing 60°C 1 min 




Genotyping was performed in 384 well-plates with 25 ng of dried down genomic DNA in each 
well. A total of 5 µL of genotyping PCR reaction mix was then added to each well; consisting 
of 1x Taqman genotyping Master Mix, 0.5x primer/probe mix made up to 5ul with DNase-free 
water. The target SNPs were genotyped in duplicate using the pre-designed primers (Life 
Technologies, US) listed in Table 2.5. The genotyping PCR program (Table 2.6) was run and 
read on the QuantStudio 7 Flex system (ThermoFisher, US). Quantstudio software was used to 
determine genotypes. Observed allele frequencies were comparable to those seen in the 1000 
Genomes Project Phase 3.  
 
Table 2. 5: Genotyping primers. 




































Table 2. 6: PCR program for genotyping 
Step Temperature Time Cycles 
Initial denaturation 95°C 10 min  
Denaturation 95°C 15 sec Repeat these 2 steps 
for 40 cycles. Anneal 60°C 1 min 
Final extension 60°C 30 sec  




 Buffers and mediums 
All buffers and media used in the experiments are outlined in Table 2.7.  
 
Table 2. 7: List buffers and mediums 
Buffer/Media Components Manufacturer 
Cell lysis buffer RIPA buffer 
Mini proteinase inhibitor cocktail 
Sigma 
Roche 
Coomassie de-stain buffer 200 mL methanol 
100 mL glacial acetic acid 
700 mL Millii-Q-H2O 
Sigma 
Fisher Chemical 
Coomassie staining buffer 1g coomassie R250 
400 mL methanol 
100 mL glacial acetic acid 




DMEM 13.7g DMEM 
1 L Milli-Q-H2O 
1 M HCL/ 1 M NaOH for pH adjustment 







FACS Buffer 1x PBS 
0.1% BSA 











1% normal donkey serum 
0.3% Trition X-100 








10% normal donkey serum 
0.3% Triton X-100 
Sigma 
Sigma 
Loading buffer NuPAGE 4x LDS sample buffer Invitrogen 
MACS Buffer 1x PBS 









RPMI  RPMI medium 1640 Life Technologies 
Running buffer NuPAGE 20x MES SDS running buffer Invitrogen 
0.1M Sodium citrate buffer 14.7 g 1 M Sodium citrate 
50 mL ethanol 
450 mL Millii-Q-H2O 
Sigma 
Sigma 
Transfer buffer 20% Methanol 
NuPAGE 20x transfer buffer 
Sigma 
Invitrogen 
TBS buffer (10x) 24.23g Tris-HCl 
5.6g Tris-Base 
87.66g NaCl 
1 L Millii-Q-H2O 









 Antibodies and dyes 
All antibodies used in Western blot, Immunocytochemistry and immunoprecipitation (Co-IP) 
are in Table 2.8. All antibodies and dyes used in flow cytometry are listed in Table 2.9. 
 
Table 2. 8: List of antibodies for immunocytochemistry, Western blot and Co-IP. 
Application Target Immunogen Host Vender 
Immunocytochemistry GPR65 36-51 Rabbit Abcam 
Western blot; Co-IP GPR65 245-275 Rabbit Abcam 
Western blot GPR65 72-89 Rabbit Bioss Antibodies 
Western blot GPR65 238-267 Rabbit LifeSpan BioSciences 
Western blot; Co-IP β-actin 1-100 Mouse Abcam 
Western blot Cofilin 150-C-terminus Mouse Abcam 
Western blot Tubulin Full length Mouse Abcam 
 
 
Table 2. 9: List of antibodies and dyes for flow cytometry. 
Marker Fluorochrome Clone Manufacturer 
Annexin V staining FITC  eBioscience 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 v500 RPA-T4 BD Bioscience 
 BUV395  BD Bioscience 
CD8 APC RPA-T8 BD Bioscience 
CD14 APC M5E2 BD Bioscience 
CD17 (Lactosyleramide) FITC Huly-m13 LifeSpan BioSciences 
CD19 BUV737 SJ25C1 BD Bioscience 
CD25 FITC M-A251 BD Bioscience 
CD56 PE B156 BD Bioscience 
CD69 v450 FN50 BD Bioscience 
Fixable far red dead stain APC-Cy7  Life Technologies 
Fixable Viability Dye eFluor 506  eBioscience 
TCR Vα24-Jα18 (iNKT 
cell) 




Chapter 3: Alternate attempts to characterise GPR65 
3.1 Introduction 
In this chapter I will describe a number of antibody based approaches which I attempted to 
employ but did not have sufficient time to adequately optimise and was therefore unable to 
utilise. Each of these methods had the potential to quantify important characteristics of GPR65 
protein expression which I had hoped to correlate with genotype. However, in each case my 
pilot efforts revealed that considerable time and resources would be required to establish a 
reliable assay, I therefore decided to focus my effort primarily on pH dependent functions and 
did not employ these methods further in my search for genotype dependent biology. 
 
Since 1975 when Kohler and Milstein described their hybridoma based technique for producing 
monoclonal antibodies, the exquisitely specific binding properties of these agents has been 
extensively used in the study of protein expression [210, 211]. Numerous biopharmaceutical 
companies now provide a wide range of protein specific monoclonal antibodies which in 
principle enable the localisation and quantification of protein expression to be studied in great 
detail. It seemed logical to begin my analysis of GPR65 using an antibody based approach to 
examine protein expression and quantification. Unfortunately, despite the fact that GPR65 has 
been recognised since the 1990s, only polyclonal GPR65 antibodies are currently available; 
furthermore, there are no published papers validating or describing the use of any of these 
antibodies. I had hoped to find a monoclonal antibody recognizing a unique GPR65 epitope in 
order to minimise non-specific binding and maximise specificity. The mouse anti-GPR65 
monoclonal antibody previously produced by TransGenic (CABT-19961MH, Creative 
BioMart; KX443) has been discontinued. The currently available polyclonal antibodies are 
listed in Table 2.9 in Chapter 2. Each was generated in rabbit by immunization with a KLH 
(keyhole limpet hemocyanin; the most common peptide carrier for immunization) conjugated 
synthetic peptide sequence from the C-terminal end of human GPR65, and purified by protein 
A antibody-binding ligands. 
 
There are no published data describing the expression of GPR65 at the protein level. However, 
at the level of transcription GPR65 has been shown to be expressed in lung, spleen, liver, bone 
marrow and immune cells; with transcription being particularly high in thymocytes and NK 
cells (Data available in the human protein ATLAS website: https://www.proteinatlas.org/). In 
mice, the transcription of GPR65 is rapidly induced by glucocorticoids (GC) [182]. In this 
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context, it seemed logical to attempt to use the available polyclonal antibodies to establish the 
expression profile of GPR65 at the protein level, with a view to subsequently exploring the 





In an attempt to determine the expression of GPR65 at the protein level in human leukocyte 
subtypes, I performed immunocytochemical staining of freshly isolated T cells (CD3+), NK 
cells (CD3- CD56+), CD3- CD56- cells, and total PBMCs from two healthy individuals using 
the Abcam polyclonal anti-GPR65 antibody (Figure 3.1). These studies showed heterogeneous 
staining in each cell type, with the highest frequency of intensely expressing cells seeming to 
occur in the CD3- CD56- population. The low-resolution microscope used to image the staining 
did not allow accurate localisation of the antibody staining relative to the DAPI nuclear staining 




Figure 3. 1: Immunocytochemistry using Abcam anti-GPR65 antibodies. Staining is shown for 
CD3+ lymphocytes (T cells), CD3- CD56+ lymphocytes (NK cells), CD3- CD56- cells and 
total PBMCs, at a magnification of x20. The manual weight parameter score is based on the 
red fluorescence to investigate the GPR65 expression in cell subtypes. 
T cells (score 3) 
Total PBMC (score 5) 
NK cells (score 4) 
CD3- CD56- cells (score 6) 
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3.2.2 Western blot 
Loading control selection 
Having detected apparent GPR65 expression in the immunocytochemistry experiment I next 
attempted to quantify this using Western blotting. To do this I first tested the suitability of β-
actin (42kD), Cofilin (20kD) and α-tubulin (57kD) as potential loading controls, by 
undertaking cell subtype specific Western blotting of these proteins in HeLa cells and 
lymphocytes from healthy controls. These efforts revealed that α-tubulin is only weakly 
expressed in human PBMCs (Figure 3.2A). While β-actin gave a band size similar to that 
expected for GPR65, and my result using cultured lymphocytes also showed that the expression 
of β-actin is significantly altered following cell proliferation and simulation (Figure 3.2B), 
further limiting its utility as a suitable control for cultured cells. I therefore concluded that for 
most of my experiments Cofilin would be the most logical protein to use as a loading control. 
 
 
Figure 3. 2: Western blotting of housekeeping proteins α–tubulin, β–actin and Cofilin. 
Comparison of α-tubulin and β-actin was made in 20 µg of lysate from Hela cells and 20 µg of 
lysate from cultured PBMCs (mainly lymphocytes) (A). Comparison of β-actin and cofilin was 

















The full length GPR65 protein includes 337 amino acids and has an expected molecular weight 
of 39kD. However, in Western blot using the Abcam polyclonal anti-GPR65 antibody I found 
a strong band at 52kD, a weak band at 20kD and only faint evidence of a band at the expected 
size of 39kD when loading high amount (30 μg) of ex-vivo PBMC protein lysate (see lane 1 in 
Figure 3.3). In cultured lymphocytes without stimulation I saw no 39kD band and an increased 
ratio of the 20kD band compared to the 52kD band (see lane 2 and independent sample in lane 
3 in Figure 3.3). Equivalent results were seen with each of the two alternate anti-GPR65 
antibodies binding to different epitopes (Bioss, US; LifeSpan BioSciences, US).  
 
 
Figure 3. 3: GPR65 expression in Western Blot. Lane 1 contains 30 µg of ex-vivo PBMC lysate 
while lanes 2 and 3 (biological replicate) contain 20 µg of lysate from lymphocytes cultured 
without stimulation for 18 hours. The lysates were loaded onto a NuPAGE Novex Bix-Tris Gel 
and expression was determined using polyclonal anti-GPR65 specific antibody (Abcam). 
Cofilin was used as a loading control. Faint evidence of a band at 39kD was only apparent in 














I next repeated the Western blot in PBMCs and specific lymphocyte subtypes from two MS 
patients and one healthy individual. Both MS samples were collected from patients attending 
the disease modifying clinic at Addenbrooke’s hospital; the first patient was on treatment with 
Fingolimod, while the second was on treatment with Copaxone. In the first MS patient, I 
observed the anticipated 39kD band as well as the 20kD and 52kD bands seen previously 
(Figure 3.4 Left). The sample from the second MS patient was separated into NK cells and T 
cells prior to loading on the Western blot (Figure 3.4 Middle). I found that the 20kD band was 
primarily expressed in the NK cells, the 52kD band primarily in the T cells and the 39kD band 
only in the remaining lymphocytes (CD3- CD56-). The cell type specific difference seen in the 
context of MS patients was less evident in a further healthy control I tested (Figure 3.4 Right). 
Given the manufactures claims of extremely high specificity for these antibodies I reasoned 
that the unexpected band sizes might be the result of post-translational modification such as 





Figure 3. 4: Western blot using the Abcam anti-GPR65 antibodies in two MS patients and in a 
healthy control. NK cells and T cells were separated from PBMCs prior to the Western blot 
analysis using autoMACS Pro Separator. 20 μg protein lysates was loaded into each well. No 







PBMC PBMC Ladder NK cells T cells CD3- CD56-
cells 




Patient 1 Patient 2 Healthy control 
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Dephosphorylation and deglycosylation 
It is known that the activity of GPR65 is regulated by phosphorylation, and that the protein 
includes three sites where N-linked glycosylation might occur (the 2nd, 79th and 166th are 
histidine residues) [183]. Either of the phosphate groups or cross-linking glycan may contribute 
to the increased size. I therefore performed dephosphorylation and deglycosylation on PBMCs 
collected from a healthy individual prior to Western blot but found that there was no significant 
effect on the 52kD band (Figure 3.5), suggesting that the observed size difference was not 
related to phosphorylation or glycosylation. 
 
3.2.3 Analysis of antibodies bound proteins 
I then reasoned that perhaps the GPR65 protein was bound with other proteins in a complex 
having a combined mass of 52kD, or that the commercially available antibodies I had been 
using might not be as specific as the manufactures claimed; i.e. were in fact binding to proteins 
other than GPR65. Since 52kD is substantially less than 2x39kD (78kD), it seems unlikely that 
this band represents a dimer of GPR65. To explore these possibilities, I attempted to use mass 
spectrometry to analyse what the proteins bound by these antibodies are. 
 
Using a PBMC and T cell lysate from a healthy individual I firstly performed SDS-PAGE 
followed by coomassie staining to separate all proteins based on their molecular weights 
(Figure 3.6). According to my previous Western blot results, the proteins at molecular weight 
52kD, 39kD and 20kD in PBMC lysate and 52kD in T cell lysate (red rectangles) were 
processed by my collaborator Dr Deery from Cambridge Centre for Proteomics at Department 
of Biochemistry and run through the mass spectrometer. Unfortunately, no human GPR65 
protein was detected. This may be due to the complex and abundant protein background in cell 
lysates, and the relatively low expression of GPR65 which may be masked by other similar 
size proteins, such as Talin-1 and pyruvate kinase enzymes, both of which were expressed 
extremely highly in all analysed proteins (Figure 3.6). A similar finding of human PBMCs 
analysed by mass spectrometry showing high expression of Talin-1 and other cytoskeletal 
proteins has recently been reported [212]. Therefore, I decided to perform protein complex 
immunoprecipitation (Co-IP) using the same GPR65 antibody to reduce the background noise, 





Figure 3. 5: Western blot using Abcam anti-GPR65 antibodies after dephosphorylation (A) and 
deglycosylation (B). PBMC lysates were collected from healthy control subjects and processed 
















































Figure 3. 6: List of PBMC lysate proteins of 52kD and their Mascot Scores identified by mass 
spectrometer. The protein bands stained by coomasive blue in red squares were cut for mass 
spectrometry analysis. The Mascot Score of the lysated PBMC protein is 52kD. Protein scores 
are derived from ions scores as a non-probabilistic basis for ranking protein hits (p<0.05). This 
graph automatically generated by mass spectrometry represents a similar finding for other 
proteins analysed including 39kD and 20kD in PBMCs and 52kD in T cells. 
  







Top 5 matching proteins: 
1. Talin-1 [Homo sapiens] 
2. Serum albumin [Homo sapiens] 
3. Albumin (Fragment) [Homo sapiens]  
4. Epididymis luminal protein 113 [Homo sapiens]  
5. Pyruvate kinase [Homo sapiens] 
53 
 
Following the Co-IP, the coomassie staining confirmed that the PBMC lysate from the healthy 
control individual I studied included only a band of 125kD (Figure 3.7A). This increased size 
is the result of bound antibodies. I then repeated the experiments using both PBMC and T cell 
lysates from other two independent healthy controls, the same band of 125kD was observed in 
both PBMC and isolated T cell lysates. Also, two faint bands at approximately 39kD and 52kD 
were also identified in T cell lysates (Figure 3.7B). I sent these samples (red rectangles) for 
analysis by mass spectrometer. The analysis showed that the protein in the 52kD band were 
most likely human keratins and Rabbit (Oryctolagus cuniculus) IgG heavy chains; in particular 
human type II cytoskeletal epidermal Keratin and Keratin 1 (Figure 3.8). Although human 
keratins have a molecular weight in the range of 44kD to 66kD, these proteins are not normally 
expressed in circulating leukocytes [213]. Similar results were observed for the 39kD protein 
in T cells and 125kD in PBMCs. Previous studies have reported that keratin from user or trypsin 
from reagents are the most common contaminating peptides [214]. Thus, given that the Abcam 
antibodies I used are rabbit IgG antibodies, it seems most likely that the faint 52kD band seen 
after Co-IP is in fact just free IgG heavy chains (which have a molecular weight of 
approximately 50kD) and sample contaminated with human keratin. Similar results were found 
for the band of 39kD suggesting that this is likely also to be a rabbit antibody fragment. In 








Figure 3. 7: Coomassie staining of precipitated proteins after Co-IP with Abcam anti-GPR65 
antibodies. Dynabead labelled Abcam anti-GPR65 antibody were used to precipitate out 
proteins and protein complexes bound by these antibodies in PBMC (A) and T cell (B) lysates. 
Antibodies were then dissociated from these bound proteins and the resulting product Western 
blotted and stained with coomassie blue. The Co-IP bands in the gel at the relevant sizes (red 
rectangles) were then cut out for mass spectrometry analysis.  




















Figure 3. 8: Mascot Score of precipitated proteins after Co-IP. Co-IP eluted proteins were 














Top 5 matching proteins: 
1. epidermal cytokeratin 2 [Homo sapiens] 
2. keratin 1 [Homo sapiens] 
3. unnamed protein product [Homo sapiens] (matched keratin family) 
4. immunoglobulin gamma1 constant region [Oryctolagus cuniculus] 
5. Ig gamma H-chain [Oryctolagus cuniculus]  
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3.2.4 siRNA transfection 
To determine the most efficiency means to measure siRNA transfection in T cells, I transfected 
freshly collected PBMCs with 2 nM pmaxGFP. In transfecting T cells I found that the 
electroporation programme V-024 was significantly (p<0.0001) more efficient (88.3%) than 
the U-014 programme (62.6%) (Figure 3.9), although the number of dead cells was calculated 
to be higher in NKT cells (U-014: 18.35%; V-024: 37.65%) and NK cells (U-014: 41.75%; V-
024: 69.9%). Further optimisation would be needed to properly optimise the balance between 
transfection efficiency and cell death. However, as I could not validate the anti-GPR65 specific 
antibody used to confirm the protein knockdown, it was no meaningful to further investigate 
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Figure 3. 9: siRNA transfection in different subtypes of lymphocytes comparing 
electroporation programmes U-014 and V-024. Cells were transfected using 2 µg pmaxGFP 
followed by culture and T cell activation. The GFP expression in harvested cells were analysed 




I had hoped that I would be able to establish an antibody based assay for GPR65 that would 
allow me to quantify GPR65 expression at the protein level, and perhaps establish its 
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expression pattern and cellular localisation. Unfortunately, each of the assays required 
extensive optimisation and I was unable to establish an adequately reliable assay in these pilot 
efforts. Although GPR65 was identified more than two decades ago [181] and has been 
characterised to some extent in mice [215], its role in humans has been studied very little. 
Recent studies in human chronic lymphocytic leukaemia (CLL) cells showed correlation 
between the mRNA expression of GPR65 and the expression of anti-apoptotic genes, 
suggesting that GPR65 might enable lymphocytes to tolerate extracellular acidosis [216]. 
Unfortunately, my pilot efforts to quantify and localise the expression of GPR65 at the protein 
level were unsuccessful. Under standard conditions I found that the available polyclonal 
antibodies did not bind to GPR65 protein, and the mass spectrometry revealed only 
contaminating by keratin and GPR65 antibody itself. As a previous study had suggested GPR65 
conformational changes by pH [196], if I had had the time I would have attempted to optimise 
the Western blot, it would have been particularly interesting to see if perhaps the anti-GPR65 
antibody binding was itself pH dependent, perhaps confirming a pH dependent conformational 
change in GPR65. In addition, the failure of the Co-IP efforts was inevitable given the lack of 
specificity in the Western blot itself. Given the lack of specificity in the Western blot it seems 
unwise to read much, if anything, into the Immunocytochemical staining of cell types; these 
results could easily be confounded by non-specific or off target binding. Given that the 
commercially available anti-GPR65 antibodies are polyclonal an alternative approach would 
have been to develop a monoclonal antibody of my own. Such an antibody would be invaluable 
for GPR65 protein expression studies in the future but would undoubtedly have taken 




Chapter 4: pH effects on lymphocyte activation 
4.1 Introduction 
In health, the extracellular hydrogen ion concentration (pH) is tightly regulated and lies slightly 
on the alkaline side of neutral; with normal values in arterial blood ranging from 7.35 to 7.45 
[217]. However, at sites of inflammation, and within tumours, the extracellular space 
frequently becomes acidic [218-222]. In mice such changes in extracellular pH have been 
shown to affect immune cell proliferation [223], NK cell cytotoxicity [224] and macrophage 
phagocytosis [225]. While in humans extracellular pH has been shown to affect immune cell 
metabolism [226], survival [227], differentiation [228], apoptosis [229] and cytotoxicity [230]. 
To further refine the effects of extracellular pH on human immune cell activation I cultured 
PBMCs with and without stimulation and assessed the expression of CD25 and CD69 in CD4+ 
T cells, CD8+ T cells, NKT cells and NK cells. To avoid any confounding related to the 
tendency for pH to fall during cell culture I employed a culture system capable of maintaining 
a stable pH throughout the duration of the experiments. 
 
In a standard culture system, a former Ph.D. student in the lab (Dr Tom Button), found 
preliminary evidence that human lymphocyte activation was reduced when the extracellular 
pH was on the alkaline side of physiological pH (pH 7.2 and pH 7.4). This reduction in 
activation seemed to be greatest in those carrying the protective minor allele at the MS 
associated SNP rs2119704. In mice, acidic pH (below pH 7.0) rather than alkaline pH has been 
shown to reduce the expression of activation markers and inhibit proinflammatory cytokine 
production [197]. Given that GPR65 is known to be sensitive to extracellular pH [183], it 
seemed reasonable to hypothesise that this gene might influence lymphocyte activation and 
function in an acidic environment, and that these effects might be important in the aetiology of 
MS. I therefore decided to explore how extracellular pH affects human lymphocyte activation.  
 
 
4.2 Determining the effects of extracellular pH on immune cells 
In order to follow up Dr Button’s findings I first wanted to establish robust methods for testing 
the effects of extracellular pH and to confirm that pH does indeed effect immune cell activation. 
To do this I undertook the following experiments; using the flow cytometry antibody panel is 




Table 4. 1: Flow cytometry staining dyes and antibody panel. 
Marker Fluorochrome Clone Manufacturer 
Annexin V staining FITC  eBioscience 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 v500 RPA-T4 BD Bioscience 
CD8 APC RPA-T8 BD Bioscience 
CD25 FITC M-A251 BD Bioscience 
CD56 PE B156 BD Bioscience 
CD69 v450 FN50 BD Bioscience 
Fixable far red dead stain APC-Cy7  Life Technologies 
 
 
4.2.1 Establishing a pH stable culture system 
In standard cultures pH tends to fall over time as cells metabolise nutrients and buffering 
capacity becomes exhausted. To avoid confounding related to such changes and to reliably 
establish the effects of extracellular pH, I first tested the stability of the culture medium pH 
after 24 and 36 hours of culture using 5 x 105 or 1 x 106 PBMCs in a final volume of 0.2 mL or 
0.5 mL per well. These efforts showed that culturing 5 x 105 cells in 0.5 mL resulted in very 
little change in the medium pH after either 24 hours or 36 hours. However, there was a dramatic 
drop in pH when 1 x 106 cells were incubated for 36 hours or in a final volume of 0.2 mL. In 
the larger volume system, with or without cultured cells, I observed that the fall in pH was less 
than 0.05 pH units during cultures of 24 or 36 hours. I also tested a HEPES buffering system 
and found similar results but decided that the sodium bicarbonate based system was optimal as 
this allowed me to ensure equivalence of pH, osmolality and sodium concentration in all 
cultures. 
 
Having established a cell culture procedure in which extracellular pH remained constant for a 
prolonged period, I next compared the most effective method for T cell activation by activating 
cells using either plate bound anti-CD3 and soluble anti-CD28 antibodies or Dynabeads™ 
Human T-Activator anti-CD3/CD28. The extent of stimulation was assessed by measuring the 
expression of late (CD25) and early (CD69) T cell activation markers; unstimulated T cells 
were used as a negative control. As expected both protocols resulted in a highly significant 
increased expression of these two markers compared with unstimulated T cells. However, the 
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plate bound anti-CD3/CD28 antibodies were more effective at stimulating T cells than the anti-
CD3/CD28 Dynabeads and I therefore elected to use these in my exploration of pH effects on 
stimulation (Figure 4.1). 
 
I next undertook a time course analysis of T cell activation in order to establish the optimal 
length of culture time to employ. In this I established cultures at differing pH and assessed the 
expression of CD25 and CD69 from total T cells, CD4+ T cells, CD8+ T cells, NKT cells and 
NK cells at multiple time points (6, 24, 30, 48, 54, 72 hours following activation with anti-
CD3/CD28 antibodies) and at different pH values (pH 6.2, pH 7.0 and pH 7.6). Results for T 
cells are shown in Figure 4.2, and indicate that maximum expression of CD25 and CD69 occurs 
within the first 24 hours. Similar results were also seen for other cell types at different pHs. 
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Figure 4. 1: Comparison of stimulation reagents. Activation of lymphocyte subtypes with plate 
bound anti-CD3/CD28 antibodies and with anti-CD3/CD28 Dynabeads. Cells were stimulated 
with 1 µg/mL plate bound anti-CD3/CD28 antibodies or 1 µg/mL anti-CD3 Dynabeads for 18 
hours. Activation was assessed as % of CD25 and % of CD69 on total T cells (A) and CD4+ T 
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Figure 4. 2: The time course analysis of lymphocyte activation at different pHs. PBMCs were 
incubated with or without anti-CD3/CD28 antibodies stimulation for up to 72 hours at pH 6.2 
pH 7.0 and pH 7.6. The maximal activation of T cells was achieved at 24 hours. Measures 
shown are the mean of technical triplicates.  
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One further concern was that my efforts might be confounded if stimulation substantially 
affected cell viability. To explore this question, I measured the viability of lymphocytes using 
Annexin V (an early stage apoptotic cell marker) and Live/Dead fixable far red stain (a dead 
cell marker) to identify the number of dead and viable cells present after culture. These 
experiments showed that the activation of lymphocytes resulted in a degree of apoptosis but 
that this was modest in cultures of less than 48 hours duration (Figure 4.3). Only 11% of cells 
were dead after 48 hours of culture, although a further one third of lymphocytes were in the 
early stage of apoptosis. This analysis also showed that lymphocyte apoptosis induced by anti-
CD3/CD28 co-stimulation was approximately three times greater than in unstimulated cells. 
Based on these data, I decided to assess the effects of pH after 18 hours of culture, a time point 
before the expression was maximal to avoid ceiling effects masking pH dependent differences, 
and before significant cell death induced by stimulation which again might confound my ability 
to detect pH dependent differences. 
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Figure 4. 3: Live/dead staining in lymphocytes after 48 hours stimulation. Cells were labelled 
with Annexin V (early apoptotic marker) and Live/Dead fixable far red stain (dead cell marker) 
after 48 hours stimulation. Flow cytometry measures are based on the mean of 5 technical 
replicates. 
 
4.2.2 Exploring the effects of extracellular pH on lymphocyte activation 
To examine the effect of extracellular pH on lymphocyte activation, I cultured cells for 18 
hours at a range of pHs (pH 6.2, 6.5, 6.8, 7.0, 7.2, 7.4 and 7.6) with and without T cell 
stimulation and determined the expression of CD25 and CD69 in specific lymphocyte subtypes 
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(total T cells, CD4+ T cells, CD8+ T cells, NKT cells and NK cells), see Figure 4.4 and 4.5. In 
the absence of stimulation extracellular pH had no effect on basal expression of CD25 but 
tended to slightly increase the expression of CD69 at acidic pH (< pH 6.8). For stimulated T 
cells an inverted U shape response curve was observed with the highest activation occurring at 
pH 7.0, although statistical analysis showed no statistically definitive differences between pH 
6.8 and pH 7.0 (p=0.0505). Either side of neutral pH the expression of CD25 declined more 
sharply at acidic pH than at alkaline pH. Considering T cell subtypes, CD4+ T cells and CD8+ 
T cells showed similar patterns of activation as assessed by CD25 expression but some 
differences were observed for CD69 proportion in stimulated cells at acidic pH. Since NKT 
cells are mainly CD8+, the pattern of CD69 expression was in fact more similar between CD8+ 
T cells and NK cell subsets (Figure 4.5). These results confirm that lymphocyte activation is 
indeed dependent upon extracellular pH, with the peak activation occurring at approximately 
pH 7.0 and both acidic and alkaline pH generally reducing activation. 
 
While NK cells are not directly stimulated by anti-CD3/CD28 antibodies, they might be 
activated in a by stander manner as a result of cytokines released by activated T cells [231, 
232]. However, I did not observe such indirect activation but instead I saw activation of both 
stimulated and unstimulated NK cells at acidic pH (Figure 4.5). This suggests that NK cells 
may become activated when the extracellular space becomes acidic. As might be expected 
NKT cells, which share properties of both T cells and NK cells [233], showed a pattern of pH 
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Figure 4. 4: Expression of CD25 and CD69 in activated human lymphocytes after 18 hours of 
culture at differing extracellular pH. Results are shown for total T cells (A), CD4+ T cells (B), 
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Figure 4. 5: Expression of CD25 and CD69 in activated human lymphocytes after 18 hours of 
culture at differing extracellular pH. Results are shown for NKT cells (A) and NK cells (B). 
Each mean ± SD is based on duplicate measures from 10 individuals. 
 
To examine whether pH or stimulation might alter the relative proportions of the different 
lymphocyte subtypes, I compared the proportion of T cells, CD4+ T cells, CD8+ T cells, NKT 
cells and NK cells. I observed that stimulation upregulated the proportion of CD4+ T cells at 
all tested pH (Figure 4.6). However, there is no significant differences in the proportion of 
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Figure 4. 6: The proportion of cultured CD4+ T cells in stimulated and unstimulated cultures. 
The proportion of human CD4+ T cells is increased by stimulation. Data were analysed by 
paired sample t-test and based on 10 individuals. 
 
 
Figure 4. 7: Human peripheral blood lymphocytes stained with FITC conjugated anti-iNKT 
cell antibodies (right) or without any antibody (left). 
 
I had hoped to be able to look specifically at iNKT cells using an antibody for the relevant T 
cell receptor Vα24-Jα18. Unfortunately, for each 100,000 lymphocytes captured there was only 
around 100 cells that were positive for Vα24-Jα18. Thus, given that iNKT cells only make up 
approximately 0.1% of the human ex-vivo lymphocyte population, it proved impossible to do 










The large volume bicarbonate based culture system I developed provides a simple method to 
maintain pH during prolonged cell culture and enabled me to reliably investigate the effect of 
extracellular pH on human lymphocytes in the context of T cell activation. This protocol 
maintains a stable medium pH for at least 24 hours without any non-CO2 dependent buffer. 
During this time, the T cell viability is maintained at around 90%. Using this system, I have 
been able to show that lymphocyte activation as assessed by CD25 expression on the cell 
surface in response to anti-CD3/CD28 stimulation is pH dependent and maximal when 
extracellular pH is neutral, i.e. slightly on the acidic side of physiological pH. While I also 
found a similar observation for CD69 expression in stimulated cells the observation of an 
increased expression of CD69 at acidic pH in unstimulated cells was unexpected. Interestingly 
a similar finding was recently reported in human lymphocytes, whereby higher expression of 
CD69 was observed in human PBMCs at acidic pH (pH 6.0) compared to pH 7.3 [234]. I 
identified that the increased expression of CD69 in unstimulated cells at acidic pH is not only 
found in both CD4+ and CD8+ T cells but was particularly prominent in NK cells. 
 
In recent work, several studies have suggested that CD69, a C-type transmembrane lectin, plays 
an essential role in regulating inflammatory responses in CD4+ T cells [235, 236], and have 
also indicated that activation of CD69 modulates Th17 lymphocyte differentiation [237, 238]. 
In NK cells the expression of CD69 is rapidly induced after activation by IL-2, IFN-α or the 
cross-linking stimulation of FcγRIII [239-242]. Furthermore, extracellular acidosis has been 
shown to inhibit the cytotoxic activity of NK cells and their production of cytokines such as 
TNF-α, INF-γ, IL-10, IL-12 and transforming growth factor-β1 [243]. In contrast, another 
study suggests acidic microenvironment enhances the microbicidal activity and perforin 
degranulation of NK cells [244]. Further work is required to establish the function of CD69 on 
both T cells and NK cells, particular in an acidic environment but my results suggests that some 
of these effects may result directly from pH sensing properties of these cells.  
 
A number of mechanisms by which cells can sense and respond to changes in the extracellular 
pH have been identified, including acid-sensing Ion channels (ASICs), transient receptor 
potential channel vanilloid subfamily 1 (TRPV1) and proton sensing G-protein coupled 
receptors (GPCRs). ASICs are sodium channels playing important roles in mechanosensation 
and synaptic plasticity that are mainly expressed on neurons in the nervous system [245, 246]. 
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TRPV1 has recently been shown to induce Ca2+ influx which contributes to CD4+ T cell 
activation and increase the pro-inflammatory cytokine production [247]. Inhibition of TRPV1 
has also been shown to suppress Th2/Th17 cytokine production in CD4+ T cells through the 
inhibition of MAP kinase [248]. The proton sensing GPCRs including GPR4, GPR65, GPR68 
(ovarian cancer G-protein couple receptor 1, ORG1), and GPR132 (G2A) have all been 
reported to be involved in inflammatory responses. Activation of GPR4 by extracellular 
acidosis induces the NF-κB pathway which in turns increase the expression of inflammatory 
genes in endothelial cells [249]. The function of GPR4 is similar to GPR65, which responds to 
extracellular pH changes through cAMP formation. GPR68 has been shown to mediate IL-8 
production in human pancreatic B cells [250], and a hyperresponse to T-cell receptor 
stimulation was reported in GPR132 deficient T cells in mice [251]. These studies highlight 
the importance of proton sensing receptors and channels on immune system regulation in 
response to extracellular pH. 
 
In summary, in this chapter I have established a simple method of undertaking cultures with a 
stable pH and using this have demonstrated that human lymphocyte activation is pH dependent 
confirming and refining the observations made by my predecessor, Dr Button. Interestingly I 
also found that an acidic extracellular pH alone is sufficient to activate an increased expression 




Chapter 5: Investigates the effect of rs74796499 genotype on 
lymphocyte activation 
5.1 Introduction 
In his pilot experiment Dr Button found preliminary evidence suggesting that the genotype at 
the MS associated SNP rs2119704 influences the extent of T cell activation between pH 7.2 - 
pH 7.4 but had no effect on the extent of activation at alkaline pH (pH > 7.4); individuals 
carrying the protective allele (A) showing lower activation than individuals homozygous for 
the risk allele (C) (Figure 1.2). Given the limited sample size in Dr Button’s pilot study (5 
protective carriers in a total of 14 healthy individuals) and his use of standard cultures, in which 
the pH will have drifted during his experiment, I wanted to see if this observation could be 
replicated using my pH stable culture system in a larger cohort of individuals. As described in 
Chapter 1 the association of MS with rs2119704, which lies in the downstream of the GPR65 
gene (Figure 5.1), was first reported in the 2011 GWAS [33], and was subsequently partially 
fine mapped in the ImmunoChip study from 2013 [151]. In the ImmunoChip study the SNP 
rs74796499 was found to be the lead (most associated) SNP in this region. 
 
 
Figure 5. 1: Map indicating the relative position of the MS associated SNPs and potential 
candidate genes on Chromosome 14q31.3. 
 
The primary aim of the work described in this chapter was thus to establish whether the MS 
associated SNP rs74796499 exerts any influence on T cell activation (as measured by the 
surface expression of CD25) at pH 7.0; this pH corresponding to the level resulting in maximal 
stimulation induced expression of CD25. Given my own additional observation that CD69 
expression was upregulated at acidic pH in both T cells and NK cells in the unstimulated state, 
I also wanted to investigate whether the MS associated SNP influenced this effect. Given that 
Chromosome 14 





GPR65 has been shown to inhibit inflammation when the extracellular pH is on the acidic side 
of physiological pH (especially below pH 7.2) [185, 193], it seems reasonable to hypothesise 
that GPR65 might be involved in acidic pH induced upregulation of CD69 on T cells and NK 
cells and that the MS associated SNP rs74796499 might influence this process.  
 
5.2 My approach to determine the effects of rs74796499 on lymphocyte 
activation 
To achieve my primary experimental aim, I measured the surface expression of CD25 on total 
T cells, CD4+ T cells and CD8+ T cells from PBMCs stimulated with anti-CD3/CD28 
antibodies for 18 hours at pH 7.0. For my secondary aim, I measured the surface expression of 
CD69 on total T cells, NKT cells and NK cells from PBMCs cultured for 18 hours at pH 6.2 
without stimulation. I then tested each of these observed measures for evidence of association 
with rs74796499. Given the low frequency of the protective allele (A) of rs74796499 in the 
British population (2% in 1000 genomes project), random collection of study subjects would 
have been highly inefficient, as practically everyone recruited in such a way would have been 
homozygous for the common (risk) allele (C). I therefore recruited healthy volunteers from the 
Cambridge BioResource so that these could be selected on the basis of their genotype and I 
was able to process samples in pairs consisting of one risk allele homozygote (C/C) and one 
heterozygote (A/C). Individuals homozygous for the protective minor allele (A/A) are rare 
(even in the BioResource) and at the time of this experiment genotyping of the BioResource 
was incomplete and only a very few individuals with this third genotype were available. I 
therefore decided not to include these at this stage. In total, I processed 23 pairs of subjects (a 
total of 46 individuals) through this pipeline. All my sample processing and expression 
measurements were conducted blind to the genotypes, which were only revealed to me after all 
samples had been fully processed and the collected data had been finalised. Ten technical 
replicates were performed to calculate a robust mean value for each expression level measured. 
The flow cytometry antibody panel I used is shown in Table 5.1. Statistical significance of 
observed differences was determined using a paired student t-test. 
 
Table 5. 1: Flow cytometry antibody panel. 
Marker Fluorochrome Clone Manufacturer 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 v500 RPA-T4 BD Bioscience 
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CD8 APC RPA-T8 BD Bioscience 
CD25 FITC M-A251 BD Bioscience 
CD56 PE B156 BD Bioscience 
CD69 v450 FN50 BD Bioscience 
 
 
5.2.1 CD25 expression on T cells stimulated at pH 7.0 
In my analysis of CD25+ T cells stimulated with anti-CD3/CD28 antibodies for 18 hours at pH 
7.0 I found no evidence for association with carriage of the protective allele (A) and CD25 
expression, in total T cells (p=0.7271), CD4+ T cells (p=0.7435) or CD8+ T cells (p=0.4043) 
(Figure 5.2). I was thus unable to replicate the effect suggested by Dr Button. 
 
























s p = 0 .7 2 7 1

























p = 0 .7 4 3 5




























Figure 5. 2: CD25 expression on T cells after 18 hours stimulated with anti-CD3/CD28 
antibodies at pH 7.0, comparing protective allele carriers (A/C, n=23) and non-carrier (C/C, 





5.2.2 CD69 expression on T cells, NKT cells and NK cells unstimulated at pH 6.2 
In my analysis of CD69 on total T cells, NKT and NK cells from 18 hours unstimulated cultures 
at pH 6.2, I found the CD69 expression on T cells is increased in individuals carrying the 
protective allele (p=0.0291) (Figure 5.3). While not significant a similar trend was observed in 
NKT cells (p=0.0689). 
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Figure 5. 3: CD69 expression on total T cells, NKT cells and NK cells from unstimulated 
cultures at pH 6.2 comparing protective allele carriers (A/C, n=23) and non-carrier (C/C, n=23); 




In these carefully conducted experiments I was unable to replicate the preliminary observations 
made by Dr Button. In my analysis I found no evidence that the MS associated SNP rs74796499 
influences T cell activation at pH 7.0, the optimal pH for T cell stimulation. However, given 
that studies in mice showed that there is little activation of GPR65 at pH 7.0, it occurred to me 
that perhaps the genotype only affects activation at more acidic pH [199]. Given that Dr Button 
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used standard culture methods the actual pH in his cultures may have drifted to lower values 
during the period of his experiments, this would not have happened during my experiments. I 
therefore decided to explore the genotype correlation experiment at a lower pH. 
 
Currently, there are four known pH sensing G protein coupled receptors, each of which is 
thought to respond to extracellular protons via the effects of these on histidine residues present 
in their extracellular domains [196, 252]. In contrast to GPR65, the receptor GPR68 (also 
known as OGR-1) exerts pro-inflammatory effects in acidic environments [253, 254], through 
increased production of IL-6 [253]. Unsurprisingly OGR-1 has also been suggested to play a 
key role in the regulation of T cell responses during autoimmunity [255]. Research on GPR4, 
which is ubiquitously expresses in all cells including lymphocytes (the human protein ATLAS 
website: https://www.proteinatlas.org/), suggests that this receptor exerts its greatest effects on 
intracellular cAMP signalling at pH 6.8 [196]. It therefore, seems reasonable to suspect that 
the effects of GPR65 might only be relevant at lower pH levels than 7.0 and that the anti-
inflammatory effects of GPR65 might be offset by other acid sensing receptors at particular pH 
values.  
 
Another possible reason for the lack of replication of Dr Button’s original finding that I have 
presented in this chapter is of course that rs74796499 may not directly affect the function of 
GPR65 at all but rather might be influencing GALC or the regulation of some other genes. In 
support of this view it is noteworthy that rs74796499 is located in an intron of GALC and is in 
complete linkage disequilibrium with 4 SNPs that are all located in GALC (shown in Appendix); 
including one synonymous coding variant (rs11552556, which is predicted to be a splice region 
variant). However, there is considerable LD associated with the minor allele of rs74796499 
such that it is also correlated with variants in GPR65 and the nearby non-coding RNA 
(LINC01146). If GALC is the relevant gene it might be that carriers of the protective allele have 
altered GALC function perhaps leading to increased level of psychosine or some other 
glycolipid. Psychosine has a direct apoptotic effect on oligodendrocytes and indirectly acts as 
an antagonist of GPR65, which inhibits the negative inflammatory function of GPR65. The 
fact that common variants known to alter the function of GALC are not associated with MS 
argues against any change in GALC function being simple. 
 
Finally, studies in knockout mice have shown that GPR65 plays an important role in the 
development of anti-collagen type II antibody-induced arthritis and delayed-type 
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hypersensitivity, both of which are believed to be T and B cell independent effects that are 
mediated by macrophages and neutrophils [193]. It is likely that the influence of rs74796499 
on risk of MS is cell type dependent, so it is possible that I have focused the efforts presented 
here in the wrong cell types. On the other hand, GPR65 is highly expressed in NK cells [174]. 
As my results to date indicate that acidic pH induces the activation of NKT and NK cells and 
that the expression of CD69 on T cells is higher in protective allele carriers it therefore seemed 
reasonable to further extend the analysis of the associated variant in T cells, NKT and NK cells 




Chapter 6: Attempts to refine the relationship between genotype 
and pH dependent expression 
6.1 Introduction 
In the previous chapters I found that the expression of CD69 was upregulated on T cells when 
the extracellular pH is acidic, and also found evidence suggesting that the extent of this 
upregulation is dependent upon the genotype at the MS associated SNP rs74796499. In this 
chapter I therefore wanted to see if I could replicate and confirm these observations, and also 
try to establish if GPR65 might be involved in mediating these effects.  To do this I repeated 
the experiments performed previously but this time included additional cultures that included 
BTB09089; a synthetic GPR65 ligand (see below) [193].  
 
I also wanted to take the opportunity provided by repeating these experiments to 
simultaneously consider the possibility that the rs74796499 variant might exert effects on the 
other protein coding gene from this region galactosylceramidase (GALC), an essential 
lysosomal enzyme responsible for the catabolism of many myelin related sphingolipids, 
including galactosylceramide, galactosylsphingosine and lactosylceramide (LacCer) through 
the hydrolysis of their galactose ester bonds. These sphingolipids are important components of 
the membrane microdomains known as lipid rafts, where they act to increase the rigidity of the 
plasma membrane so that it can link to the cellular cytoskeleton and hold together the clusters 
of molecular components required in cell surface functional units [256, 257]. The role of lipid 
rafts in signal transduction has been shown to be important in the pathogenesis of various 
diseases including Alzheimer’s disease, Parkinson’s disease and systemic lupus erythematosus 
(SLE) [258]. Recent studies indicate lipid rafts also play a key role in immune cell activation 
[259, 260], via T cell receptor (TCR) and the Fc regions (FcR) of the B cell receptor (BCR) 
[261]. It therefore, seemed reasonable to hypothesise that altered lipid metabolism might alter 
lipid raft formation and thereby affect lymphocyte functioning. In support of this it is known 
that LacCer, an important intermediate in the catabolism of many of the complex 
glycosphingolipid found in myelin, is involved in cell-cell interaction and signalling 
transduction [262, 263]. A recent study found that the expression of LacCer and of its synthase 
enzyme (B4GALT6) is upregulated in astrocytes in MS lesion; both of which are involved in 
the recruitment and activation of CNS infiltrating monocytes and microglia in EAE [264]. This 
research group also observed inhibition of local CNS innate immunity when LacCer synthesis 
was inhibited, with resulting protection from EAE [264]. Increased expression of lipid raft-
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associated glycosphingolipids, including LacCer, globotriaosylceramide (Gb3) and 
monosialotetrahexosylganglioside (GM1) has also been observed in CD4+ T cells from 
patients with SLE [265, 266]. So in the repeat experiments described in this chapter I decided 
to measure LacCer in ex-vivo cells. 
 
As described in Chapter 1 the neurodegeneration seen in Krabbe’s Disease (the autosomal 
recessive demyelinating disease resulting from loss of function mutations in GALC) is thought 
primarily to results from the toxic effects of the galactosyl-sphingolipid psychosine [167]. This 
moiety is a naturally occurring ligand for GPR65, and thus, although at face value the two 
genes from this region don’t seem to have any immediately obvious relationship to each other, 
in fact one of the most important substrates for the one gene (GALC) is a ligand for the second 
(GPR65). Furthermore, given that galacto-sphingolipids are almost exclusively found in 
nervous tissue it seems likely that this interaction will be particularly relevant in areas of CNS 
inflammation where myelin breakdown will result in large amounts of galactosphingolipids 
needing to be catabolised and inflammation will result in reduction of local pH. 
 
 
6.2 The synthetic GPR65 ligand - BTB09089 
Given that activation of GPR65 has been shown to reduce the production of pro-inflammatory 
cytokines, and that knocking this gene out in mice results in exacerbation of various immune 
mediated inflammatory diseases [193, 206] Onozawa et al screened a library of compounds 
looking for an agonist for this receptor and found the molecule (3-[(2,4-dichlorobenzyl)thio]-
1,6-dimethyl-5,6-dihydro-1H-pyridazino[4,5-e][1,3,4] thiadiazin -5-one) which they 
designated BTB09089. Despite the extensive homology between GPR65 and other acid-
sensing G-protein coupled receptors, such as OGR1 and GPR4, BTB09089 has been shown to 
only activate GPR65 [193, 267] and has also been shown to reduce the production of IL-2 from 
splenocytes stimulated with anti-CD3/CD28 antibodies [193]. This molecule thus seems to act 
as a highly selective agonist of GPR65 and thus provides a means to test whether GPR65 is 
involved in the pH dependent effects I saw previously. However, because BTB09089 is 
hydrophobic I first needed to solubilise it, and to do this I used DMSO (as recommended by 
the manufacturer). In order to ensure that the use of DMSO in this way would not influence 
my results, I tested the effects of DMSO itself on my cultures and found that at concentrations 
up to 1% (v/v) DMSO did not significantly alter the expression of CD25 or CD69 on any of 
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the lymphocyte subtypes I wanted to test, or their relative proportions (Figure 6.1). It is well 
established that DMSO does not have any significant short term cytotoxic effect on 
lymphocytes at concentrations less than 1% (v/v) [268-270]. Having established that the use of 
DMSO would not confound my experiments I next performed a BTB09089 titration 
experiment with and without anti-CD3/CD28 stimulation at pH 7.0 (Figure 6.2). This 
confirmed that at the tested concentrations BTB09089 had no effect on the relative proportions 
of the different cell subtypes but substantially reduced the expression of both CD25 and CD69 
in the stimulated cultures in a concentration dependent manner. My results were consistent 
with those from previous investigators [193] with a substantial effect at a concentration of 20 
μM; which required the use of only 0.2% (v/v) DMSO. I then tested this concentration of 
BTB09089 in stimulated cultures at a range of pH values (Figure 6.3) and confirmed that it 
suppressed expression of CD25 and CD69 in all cases, although the effects in NK cells were 































































































































































































Figure 6. 1: Influence of DMSO on PBMCs cultured for 18 hours at pH 7.0. The proportion of 
lymphocyte subtypes (A), expression of CD25 (B) and CD69 (C) were assessed. Data is based 









































































































































































































































































































































































Figure 6. 2: BTB09089 titration assay. PBMCs were cultured at pH 7.0 for 18 hours 
unstimulated and stimulated in the presence of a range of BTB09089 concentrations. The 
proportion of lymphocyte subtypes in unstimulated (A) and stimulated (B) condition are shown 
together with the expression of CD25 and CD69 in unstimulated (C and E) and stimulated (D 
and F) cultures in each of the cell types to be considered. These data are based on testing one 
subject in duplicate. 
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Figure 6. 3: BTB09089 induced suppression of CD25 and CD69 expression in stimulated 
cultures across a range of pHs. PBMCs were stimulated with anti-CD3/CD28 antibodies 
supplemented with 20 μM BTB09089 for 18 hours at pH 6.2, pH 7.0 and pH 7.6. Expression 
of CD25 (A) and CD69 (B) on total T cells, and CD69 on NK cells (C) were assessed. Data 
are based on one subject tested in duplicate. 
 
 
6.3 Replication experiment outline 
In this phase of my work, I processed samples from 50 healthy individuals (25 heterozygotes 
and 25 major risk allele homozygotes) that were all recruited from Cambridge BioResource on 
the basis of their genotype. Samples were collected and processed in genotype matched pairs 
with one homozygote (C/C) and one heterozygote (A/C) in each pair. I was blind to the 
genotypes until all sample processing and measurements had been completed and finalised. For 
each individual, I measured the surface expression of LacCer (CD17) on freshly collected ex-
vivo T cells, CD4+ T cells, CD8+ T cells, NKT cells and NK cells. I also separated CD56+ 
cells (NKT and NK cells) and CD56- cells using the autoMACS Pro Separator and extracted 
RNA from these cells as described in Chapter 2. In parallel to processing the ex-vivo cells I 
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also set up three PBMC cultures at pH 6.2 and three at pH 7.0. At each pH one culture was 
established with anti-CD3/CD28 stimulation alone, a second was established with anti-
CD3/CD28 stimulation in the presence of BTB09089, and a third was unstimulated (with no 
anti-CD3/CD28 antibodies and no BTB09089). Following 18 hours incubation of each of the 
6 cultures I measured the surface expression of CD25 and CD69 on total T cells, CD4+ T cells, 
CD8+ T cells, NKT cells and NK cells. The flow cytometry antibody panels used for the ex-
vivo cell analysis and the cultured PBMC analysis are shown in Table 6.1 and Table 6.2 
respectively. For each measure I performed four technical replicates. Because the samples were 
supplied from the Cambridge BioResource in pairs I was able to analyse the resulting protein 
expression data using a paired student t-test which controls for any batch effect differences 
related to processing the samples on different days. For each of the five cell types (total T cells, 
CD4+ T cells, CD8+ T cells, NKT cells and NK cells) I measured CD17 in ex-vivo cells and 
CD25 and CD69 in each of the 6 culture settings. In each of the 6 culture settings I also 
measured CD25 and CD69 expression in the residual lymphocytes (i.e. the cells that were CD3- 
and CD56- and are therefore B cell enriched) and in the NKT cells that were also CD8+. There 
was no meaningful expression of CD25 in NK cells or in the B cell enriched residual cells 
(those that were both CD3- and CD56-) so no analysis was made for these groups. This gives 
a total of 77 expression phenotypes that were tested for association with genotype. Since many 
of these expression phenotypes are necessarily correlated the effective number of independent 
phenotypes was established using an R script provided by Prof Frank Dudbridge (using 10,000 
permutations). This script, which determines the effective number of independent phenotypes 
empirically, showed that my 77 phenotypes were equivalent to 37.6 independent phenotypes 
and I therefore set a threshold of p<0.0013 for declaring statistical significance in order to 
correct for multiple testing. 
 
In addition, I also measured cell proportions. In the ex-vivo cells I measured the % of 
lymphocytes that were T cells, NKT cells and NK cells, and also measured the proportion of 
NKT cells that were CD8+, the proportion of CD4+ T cells and CD8+ T cells, and the ratio of 
CD4+/CD8+ T cells.  In each of the 6 culture settings I measured the % of lymphocytes that 
were of each subtype (total T cells, CD4+ T cells, CD8+ T cells, NKT cells, NK cells and 
CD8+ NKT cells). In each of the 6 culture settings I also measured the proportion of T cells 
that were CD4+, CD69+ and CD25- (this set of cells has been suggested to act as a new subset 
of regulatory T cells, that inhibits T cell proliferation) [236], the % of lymphocytes that were 
both CD4+ and CD69+ and the % of lymphocytes that were CD4+, CD69+ and CD25+. In 
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total, I thus measure 61 proportions which again are extensively correlated. Using the script 
from Prof Dudbridge these were found to be equivalent to 29.6 independent phenotypes and I 
therefore set a significance threshold of 0.0017 to correct for multiple testing in this group of 
tests.  
 
Table 6. 1: Flow cytometry antibody panel for LacCer experiment on ex-vivo cells. 
Marker Fluorochrome Clone Manufacturer 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 BUV737 SK3 BD Bioscience 
CD8 APC RPA-T8 BD Bioscience 
CD56 PE B156 BD Bioscience 
LacCer FITC Huly-m13 LifeSpan Biosciences 
 
Table 6. 2: Flow cytometry antibody panel for GPR65 functional assay on cultured cells. 
Marker Fluorochrome Clone Manufacturer 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 BUV737 SK3 BD Bioscience 
CD8 APC RPA-T8 BD Bioscience 
CD25 FITC M-A251 BD Bioscience 
CD56 PE B156 BD Bioscience 
CD69 v450 FN50 BD Bioscience 
 
 
6.3.1 LacCer (CD17) expression in ex-vivo cells 
In my analysis of ex-vivo cells I found evidence that was just significant after correcting for 
multiple testing that carrying the protective allele at rs74796499 (A) reduces the LacCer 
expression on the surface of T cells, with similar effects in both CD4+ and CD8+ subtypes 
(Figure 6.4). The same trend is seen in NK cells but this does not remain significant after 
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Figure 6. 4: LacCer expression on ex-vivo lymphocytes. Carriers of the protective allele (A/C) 
and non-carriers (C/C) are compared for total T cells (A), CD4+ T cells (B), CD8+ T cells (C), 
NKT cells (D) and NK cells (E).  
 
6.3.2 CD25 and CD69 expression after pH specific cultures 
As anticipated BTB09089 suppressed both CD25 and CD69 expression in stimulated cultures 
with a much larger effect in the acidic extracellular environment (pH=6.2) than at neutral pH 
(pH=7.0) (Figure 6.5 and 6.6). These differences at both pH are all statistically significantly 
different with p<0.0001 (unstimulated vs stimulated; stimulated vs stimulated with BTB09089) 
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Figure 6. 5: CD25 and CD69 expression in total T cells (A), CD4+ T cells (B) and CD8+ T 
cells (C) unstimulated (green), stimulated without BTB09089 (red) and stimulated with 
BTB09089 (blue) in 18 hours cultures at pH 6.2 and pH 7.0. Histograms are based on the mean 
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Figure 6. 6: CD25 and CD69 expression in NKT cells (A) and NK cells (B) unstimulated 
(green), stimulated without BTB09089 (red) and stimulated with BTB09089 (blue) in 18 hours 
cultures at pH 6.2 and pH 7.0. Histograms are based on the mean expression across all 50 
samples with 4 technical replicates for each individual. 
 
6.3.3 Surface expression of CD69 
Figures 6.7, 6.8, 6.9, 6.10, 6.11, 6.12 and 6.13 show the effects of rs74796499 genotype on 
CD69 expression in each culture setting and at each pH for total T cells, CD4+ T cells, CD8+ 
T cells, NKT cells, CD8+ NKT cells, NK cells and B cell enriched lymphocytes (CD3-, CD56-) 
respectively. In keeping with my earlier results in unstimulated cultures at acidic pH (pH=6.2) 
I saw greater expression of CD69 in T cells from individuals carrying a protective allele at 
rs74796499 (Figure 6.7) although this difference did not survive correction for multiple testing. 
In Chapter 5, I measured CD69 in total T cells, NKT cells and NK cells after 18 hours of 
cultures at pH 6.2 (without anti-CD3/CD28 stimulation or BTB09089) in 23 genotyped 
matched pairs (46 individuals). Eleven of these subjects were also included in the analysis 
described in this chapter; including one complete genotyped matched pair and nine single 
individuals from other pairs. Removing the 11 overlapping subjects from the Chapter 5 data 
together with their 9 counterpart subjects left a total of 13 genotype matched pairs (26 
individuals) that were non-overlapping with the data described in this chapter. Combining the 
non-overlapping data enabled an analysis of 38 genotyped matched pairs (76 individuals) for 
CD69 expression in total T cells, NKT cells and NK cells after 18 hours of unstimulated culture 
at pH 6.2 (without BTB09089), but there was no meaningful change in the results, with no 
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significant evidence of any genotype dependent difference in NKT cells or NK cells, but a 
higher proportion of CD69 positive T cells in the protective allele carriers (Figure 6.14). 
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Figure 6. 7: Expression of CD69 on total T cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 8: Expression of CD69 on CD4+ T cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 9: Expression of CD69 on CD8+ T cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 





























p = 0 .3 7 6 7
A

























p = 0 .4 6 4 1
B

























p = 0 .2 1 1 2
C

























p = 0 .7 8 3 9

























p = 0 .9 2 9 2

























p = 0 .9 6 7 8
p H  6 .2 p H  7 .0
 
Figure 6. 10: Expression of CD69 on NKT cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 11: Expression of CD69 on CD8+ NKT cells in protective allele carriers (circles) and 
risk allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each 
of the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 12: Expression of CD69 on NK cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 13: Expression of CD69 on CD3- CD56- lymphocytes in protective allele carriers 
(circles) and risk allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and 
pH 7.0 for each of the three culture settings; unstimulated (green), stimulated in the absence of 
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Figure 6. 14:  Expression of CD69 on total T cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 without any stimulation 
with anti-CD3/CD28 antibodies and without any BTB09089. 
 
 
6.3.4 Surface expression of CD25 
Figures 6.15, 6.16, 6.17, 6.18 and 6.19 show the effects of rs74796499 genotype on CD25 
expression in each culture setting and at each pH for total T cells, CD4+ T cells, CD8+ T cells, 
NKT cells and CD8+ NKT cells (the number of CD25 positive NK cells or enriched B cells is 
very low, these cell types were therefore not analysed). Extending the analysis for T cells, 
CD4+ T cells and CD8+ T cells for the stimulated without BTB09089 at pH 7.0 using the data 
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Figure 6. 15: Expression of CD25 on total T cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 16: Expression of CD25 on CD4+ T cells in protective allele carriers (circles) and 
risk allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each 
of the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 17: Expression of CD25 on CD8+ T cells in protective allele carriers (circles) and 
risk allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each 
of the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 18: Expression of CD25 on NKT cells in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 19: Expression of CD25 on CD8+ NKT cells in protective allele carriers (circles) and 
risk allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each 
of the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
and stimulated in the presence of BTB09089 (blue). 
 
 
6.4 Cell subtype proportion results 
6.4.1 Cell subtype proportions in ex-vivo cells 
Figures 6.20 shows the influence of the rs74796499 genotype on the proportion of ex-vivo T 
cells, CD4+ T cells, CD8+ T, NKT cells and CD8+ NKT cells and NK cells, as well as the 
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CD4/CD8 ratio. Although the p value did not survive correction for multiple testing, this 
analysis revealed a trend towards rs74796499 genotype influencing the CD4/CD8 ratio. 
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Figure 6. 20: The influence of genotype on the proportion of T cells that were CD4+ and CD8+, 
NKT cells and NK cells in ex-vivo cells, also the percentage of NKT cells that were CD8+. 
Figure (G) shows the ratio of CD4+/CD8+ T cells in ex-vivo cells. 
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6.4.2 Proportions of T cell subtypes after culture 
Figures 6.21, 6.22 and 6.23 show the effects of rs74796499 genotype on cell subtype 
proportions in each culture setting and at each pH for the proportion of T cells that are CD4+, 
CD8+, and the ratio of CD4/CD8.  
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Figure 6. 21: Proportion of T cells that are CD4+ in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
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Figure 6. 22: Proportion of T cells that are CD8+ in protective allele carriers (circles) and risk 
allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of 
the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
and stimulated in the presence of BTB09089 (blue). 
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Figure 6. 23: The CD4/CD8 ratio in protective allele carriers (circles) and risk allele 
homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each of the 
three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) and 




6.4.3 Proportion of NKT cells that are CD8+ 
In each of the culture settings I found that on average the proportion of NKT cells that are 
CD8+ (also known as CD8+ T cell that are CD56+) was lower in individuals carrying the 
protective allele than in risk allele homozygotes (Figure 6.10), with all but one of these 
differences being nominally significant but again none survived correction for multiple testing.  
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Figure 6. 24: Proportion of NKT cells that are CD8+ in protective allele carriers (circles) and 
risk allele homozygotes (inverted triangles) after 18 hours culture at pH 6.2 and pH 7.0 for each 
of the three culture settings; unstimulated (green), stimulated in the absence of BTB09089 (red) 
and stimulated in the presence of BTB09089 (blue). 
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6.5 MS associated variant - rs11052877 
Given of the suggestion that the expression of CD69 might be influenced by the genotype at 
rs74796499 it seemed logical to also consider the effects of rs11052877, an independent SNP 
which was identified as a susceptibility variant in the MS Immunochip study and maps to the 
3’ UTR of the CD69 gene on chromosome 12p13 [151]. I therefore genotyped the rs11052877 
variant in my 50 samples and found 18 protective allele homozygotes (A/A), 26 heterozygotes 
(A/G) and 5 risk allele homozygotes (G/G). I then tested the CD69 expression data from each 
of the cell types in each of the culture settings for association with this SNP. Since all three 
genotypes were included in this data set I completed the analysis using the logistic regression 
option in PLINK. Because the paired processing of samples was based on the genotype at 
rs74796499 many of these pairs had the same genotype at rs11052877, I was therefore not able 
to include the pair ID as categorical covariates. The results for each cell type are shown in 
Figures 6.25, 6.26, 6.27, 6.28, 6.29 and 6.30. As with rs74796499 a trend towards higher 
expression in carriers of the rs11052877 protective allele was seen in many cells subtypes; this 
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Figure 6. 25: Expression of CD69 on total T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), stimulated in 
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Figure 6. 26: Expression of CD69 on CD4+ T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), stimulated in 
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Figure 6. 27: Expression of CD69 on CD8+ T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), stimulated in 
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Figure 6. 28: Expression of CD69 on NKT cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), stimulated in 
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Figure 6. 29: Expression of CD69 on CD8+ NKT cells in protective allele homozygotes 
(circles), heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 
hours culture at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), 
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Figure 6. 30: Expression of CD69 on NK cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), stimulated in 




6.6 Investigating mRNA expression in ex-vivo cells 
In the RNA I collected from CD56+ and CD56- ex-vivo cells, I measured the mRNA 
expression of GPR65, GALC and CD69 using quantitative PCR. As described in Chapter 2 this 
expression was quantified relative to the housekeeping gene β-ACTIN using the standard curve 
method. I found no evidence that either of the MS associated SNPs (rs74796499 and 
rs11052877) influenced the mRNA expression of these genes (Figures 6.31 and 6.32). In short, 
I found no evidence to suggest that either of these SNPs are expression Quantitative Trait Loci 
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Figure 6. 31: GPR65 (A), GALC (B) and CD69 (C) mRNA expression in CD56+ cells (left 
hand panels) and CD56- cells (right hand panels) comparing rs74796499 heterozygotes (A/C) 
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Figure 6. 32: GPR65 (A), GALC (B) and CD69 (C) mRNA expression in CD56+ cells (left 
hand panels) and CD56- cells (right hand panels) comparing rs11052877, protective allele 
homozygotes (A/A), heterozygotes (A/G) with risk allele homozygotes (G/G). 
 
In 2016 the results from a Sardinian eQTL study became available online and on searching 
these I identified an eQTL for GPR65 in PBMCs, rs3943657 (p=1.49e-21) [271]. At that time, 
I could not find any other publicly available databases listing eQTLs for GPR65 or GALC in 
immune related tissues. I successfully genotyped 45 of my 50 subjects for rs3943657 (5 
samples failed to genotype) and tested these data for evidence of association with the 
expression of GPR65 as a positive control. I replicated the Sardinian observation that this SNP 
is indeed an eQTL for GPR65 (Figure 6.33). 
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Figure 6. 33: GPR65 mRNA expression in CD56+ cells (left hand panel) and CD56- cells (right 
hand panel) comparing rs3943657 minor allele homozygotes (G/G, n=3), heterozygotes (G/T, 
n=22) and major allele homozygotes (T/T, n=20). NB 5 samples failed to genotype in this assay. 
 
 
6.7 Analysis of additional potentially related SNPs 
Although rs74796499 appears to only be relevant in MS, genome-wide analysis of other 
autoimmune diseases has identified independent genetic variants from the chromosome 
14q31.3 region that influence the risk of Crohn’s disease (rs8005161) [179] and ankylosing 
spondylitis (rs11624293) [180]; as described in Chapter 1 these variants are perfect proxies for 
each other indicating that it is likely that a variant in this region influences the risk of both these 
diseases. In the inflammatory bowel disease (IBD) ImmunoChip study rs28533072 emerged as 
the lead SNP driving the Crohn’s association [272]. In my data I found no evidence that this 
SNP influences the expression of GPR65 or GALC in lymphocytes (Figure 6.34). However, in 
my cell subtype proportions data I observed a nominally significant trend suggesting that the 
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Figure 6. 34: GPR65 and GALC mRNA expression in CD56+ cells (left hand panel) and CD56- 
cells (right hand panel) comparing rs28533072 major allele homozygotes (C/C, n=29), 
heterozygotes (C/T, n=14) and minor allele homozygotes (T/T, n=2). NB 5 samples failed to 
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Figure 6. 35: Proportion of NKT cells that are CD8+ in rs28533072 major allele homozygotes 
(circles), heterozygotes (inverted triangles) and minor allele homozygotes (squares) after 18 
hours culture at pH 6.2 and pH 7.0 for each of the three culture settings; unstimulated (green), 
stimulated in the absence of BTB09089 (red) and stimulated in the presence of BTB09089 
(blue).  
 
In the MS ImmunoChip study phosphoglycerate dehydrogenase (PHGDH) was highlighted as 
a potential candidate susceptibility gene [151], with rs666930 listed as the lead (most 
associated) SNP. Since this enzyme catalyses the rate limiting step in the synthesis of the amino 
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acid L-serine, which is an essential precursor required for the formation of myelin glycolipids, 
it seemed logical to also look for any association of this SNP with my results. Especially since 
in their metabolomics GWAS Shin et al. had clearly demonstrated that cis genetic variation in 
the region of PHGDH significantly influenced the circulating level of L-serine [273]. 
Unfortunately, the lead SNP from the metabolomics GWAS (rs1163251) was not genotyped in 
the ImmunoChip study [274], which included very few markers in this region of the genome. 
There is only very modest LD (r2=0.1) between rs1163251 and rs666930 but no better tag SNPs 
were included on ImmunoChip. Looking further at the list of established MS susceptibility loci 
I noticed that one of the other associated SNPs, rs17785991 from chromosome 20q13, maps 
close to another myelin glycolipid relevant gene, B4GALT5, a key beta-galatosyltransferase 
enzymes [151]. In the latest results from the IMSGC meta-analysis, I found a further MS 
associated SNP (a low frequency variant) that also maps to the region containing the B4GALT5 
gene, rs6020055 [37]. Given the relevance of these genes in sphingolipid metabolism I 
genotyped these three SNPs (rs666930, rs6020055 and rs17785991) in my 50 samples; 
unfortunately, none of these showed any evidence of association with the expression of LacCer 
(CD17). 
 
Analysis of rs7476499 was performed using a paired t-test (as this cohort was recruited to 
contain just 2 genotypes), while other SNPs were analysed using the logistic regression option 
in PLINK. The pair IDs were not included as covariates, but covariates were included based 




Many studies have shown that glycosphingolipids are important in the development of Th17 
cells. For example, intracellular lipidome biosynthesis has been suggested to influence the 
quality and/or quantity of available RORγt ligand, and thereby affect the differentiation of 
helper cells into a Th17 phenotype [275]. Similarly, altering the glycosphingolipid composition 
of lipid rafts by reducing glycosphingolipid level in CD4+ T cells has been found to inhibit the 
Th17 cell differentiation [276]. LacCer is involved in multiple signal transduction pathways 
that lead to critical phenotypic changes in cells, and has been shown to be important in diverse 
processes including cell proliferation, adhesion, autophagy, inflammation and apoptosis [277-
280]. LacCer is also involved in signalling and has been shown to regulate the activation of 
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astrocytes and influence the development of EAE [281]. The activity of adhesion molecules 
such as intercellular adhesion molecule 1 (ICAM-1) in monocytes and neutrophils has also 
been shown to be regulated by the expression of LacCer on the cell membrane [278]. In this 
context it seems reasonable to speculate that the genotype dependent changes I have seen in 
LacCer expression could result in important differences in the function of lymphocytes from 
rs74796499 protective allele carriers. 
 
It’s not immediately clear how rs74796499 might alter the expression of LacCer. Given that 
GALC is involved in the metabolism of glycolipids, it’s possible that the change in LacCer 
might perhaps result from a change in the enzyme activity of GALC. However, since none of 
the common coding variants in GALC that are known to influence the catalytic activity of the 
enzyme (rs398607 (p.Ile562Thr), rs1805078 (p.Arg184Cys) and rs34362748 (p.Asp248Asn)) 
are associated with MS [282], it seems unlikely that any effects of rs74796499 on GALC is a 
simple as changing its catalytic activity. I found no evidence that rs74796499 alters the 
expression of GALC itself. However, the lead MS associated variant rs74796499 is in tight LD 
with a coding variant in GALC (rs11552556), which is predicted to be a splice region variant. 
The effect of this variant on GALC alternate transcription is at present unknown. In IBD the 
coding variant in GPR65, rs3742704 (I231L) has been suggested to alter the lysosomal pH and 
could thus affect the activity of GALC. However, the Crohn’s disease associated variation from 
this region (which is in LD with this functionally relevant GPR65 coding variant) is not 
associated with MS and does not affect any of the phenotypes I measured. There is little LD 
between the MS associated variant rs74796499 and the Crohn’s associated variant rs28533072 
(R2=0.02) but it remains possible that the MS variant might also influence lysosomal pH but in 
a different setting.  
 
Despite suggestions to the contrary [193, 200] I found that BTB09089 is highly efficient at 
suppressing the activation of lymphocytes induced by anti-CD3/CD28 antibodies. Further 
studies are required to determine if BTB09089 can influence the expression of CD69 (or 
whether this agent might have blocked the influence of genotype on this acid induced 
expression).  
 
In this chapter I successfully replicated my previous observation that CD69 expression is 
induced by culturing cells in an acid microenvironment and that the extent of this expression 
is dependent upon the genotype at the MS associated SNP rs74796499, but because of sample 
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overlap did not greatly increase the statistical significance of the evidence supporting this 
association in a combined analysis. In addition, I found that the independent associated SNP 
rs11052877 showed a trend towards a similar influence on the expression of CD69. For each 
of these two SNPs the protective allele increased the expression of CD69 suggesting that 
increased expression of CD69 on T cells in areas of inflammation (where pH will be acidic) is 
protective in MS. CD69 is a type II transmembrane glycoprotein with a C-type lectin domain 
in the extracellular side of the plasma membrane [283]. CD69 is considered an early activation 
marker in various lymphocyte subsets, and recent studies have indicated that CD69 has immune 
regulatory functions [284-286]. CD69 knockout mice have an increased propensity towards 
chronic inflammation, including collagen-induced arthritis [287], allergic asthma [238] and 
autoimmune cardiomyopathy [288], with recent studies suggesting that the increased 
susceptibility of these mice to different inflammatory diseases is primarily mediated via effects 
on Th17 cells [289]. Quite how CD69 influences the balance between Treg and Th17 cells is 
unclear. It has been shown that CD69 inhibits sphingosine 1-phosphate receptor (S1P1) 
signalling via the mTOR/HIF1a and JAK2/STAT3 pathways both of which are important in 
the development of the Th17 phenotype [290-292]. Sphingosine-1-phosphate (S1P) is involved 
in extracellular signalling [293-295] and influences astrocytosis in mice [296]. Clinical trials 
have shown that Fingolimod, an S1P receptor modulator, is an effective disease modifying 
treatment for MS [297, 298]. Lipid rafts, and therefore LacCer and other glycosphingolipids, 
are important at cell surface sites where CD3/CD28 stimulation occurs and where CD69 is 
expressed [299, 300].  
 
In addition, there are data suggesting that CD69 is important in maintaining the balance 
between the master transcription factors in Treg (Foxp3) and Th17 cells (RORγt) through the 
JAK/STAT5 intracellular pathway [238, 301, 302]. Furthermore, GPR65 knockout mice have 
been shown to produce less IL-17A and to be resistant to the development of EAE [275]; and 
ChiP-seq analysis has shown that RORγt (the Th17 cell master transcription factor) binds to 
the GPR65 promoter region [275]. Given my analysis showing that the MS associated SNP 
rs74796499 influenced CD69 expression it is possible that the MS associated variant 
rs74796499 influence the Th17 and Treg balance through the regulation of CD69 expression. 
 
It is also worth remembering that GPR65 was first identified through its involvement in 
thymocytes apoptosis mediated by T cell receptor engagement, suggesting the gene might have 
a role in the negative selection of thymocytes [181] and thus that the MS associated variant 
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might exert its effect by altering the balance of lymphocyte subtypes or numbers. Studies where 
GPR65 was over expressed lewis lung carcinoma (LLC) cells showed enhanced cell 
proliferation and glycolysis [199] while GPR65 knockout mice showed normal immune 
development and glucocorticoid-induced thymocyte apoptosis [182]. In my analysis I found 
that the proportions of T lymphocyte subtypes were not significantly influenced by the MS 
associated SNP rs74796499, suggesting that any involvement of GPR65 in apoptotic functions 
may not be of critical importance. 
 
In conclusion I validated and partially replicated my earlier observation that carrying the 
protective allele at rs74796499 increases the expression of CD69 on T cells cultured in acidic 
microenvironments, and extended this by showing that this allele might also reduce the 
expression of LacCer (CD17) on human T cells. Given the known roles of CD69 and LacCer 
in T cell development it is possible that the genotype dependent changes induced by the 
protective alleles at these SNPs favour the development of Tregs over Th17 cells and thereby 




Chapter 7: Lysosomal pH 
7.1 Introduction 
Lysosomes are membrane-bound organelles that contain hydrolytic enzymes required for the 
breakdown of both extracellular and intracellular biomolecules, including proteins, nucleic 
acids, carbohydrates and lipids [303]. Loss of function mutations in the genes that encode these 
enzymes result in the accumulation of substrates that cannot be metabolised by alternate means 
and produce so called “lysosomal storage diseases”. For example, in Gaucher’s disease 
homozygous (or compound heterozygous) mutations in the GBA (Glucosylceramidase beta) 
gene on chromosome 1, result in the intracellular accumulation of glucosylceramide [304, 305], 
while in the much rarer Sandhoff disease (SD) mutations in the HEXB (hexosaminidase B) 
gene from chromosome 5 results in the accumulation of the brain lipid GM2 ganglioside [306]. 
These lysosomal enzymes require an acidic environment for their optimal activity, and 
therefore the pH in lysosomes is typically maintained between 4.6 and 5.0 [307]. Active proton 
transports (proton pumping V-type ATPase) and ion channels in the lysosomal membrane 
maintain this pH which is substantially below the cytoplasmic pH of 7.2 [307, 308]. The 
extracellular material degraded in lysosomes through processes such as endocytosis, 
phagocytosis and autophagy include lipid molecules many of which are recycled back into 
metabolism via lysosomes [309-311]. A bidirectional relationship exists between lipids and 
lysosomes, with lysosome activity regulating lipid metabolism, and lipids in turn regulating 
lysosomal function [312]. 
 
Given the observation in IBD that activation of GPR65 influences the metabolism of 
glycosphingolipids by altering lysosomal pH it seemed logical to explore whether the MS 
associated variant rs74796499 might also exert effects on lysosomal pH. To investigate this, I 




7.2 LysoSensor dye 
Thermo Scientific manufacture a range of fluorescent LysoSensor dyes. Ideally, I would have 
liked to use their LysoSensor Yellow/Blue DND-160 system which employs a yellow dye with 
a peak florescence in acidic environments together with a blue dye with a peak florescence in 
alkaline conditions. The ratio of these two emissions thus enabling a determination of the actual 
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pH. Unfortunately, this kit, which is primarily designed for fluorescence microscopy work, is 
currently incompatible with flow cytometry (BD Fortessa). I therefore used a single dye system 
(LysoSensor Yellow DND-189) and chose a dye with an emission spectra that was as different 
as possible from the other fluorophores I needed to use in the antibody panel. This dye reaches 
all intracellular compartments but only fluoresces in those with an acidic pH, and therefore 
effectively only reflects the pH of the acidic intracellular organelles, which are primarily the 
lysosomes. Because only one colour dye was used all measures were relative rather than 
absolute, with higher emission corresponding to lower (more acidic) pH. To measure lysosomal 
pH in specific immune cell subtypes from ex-vivo PBMCs I used the flow cytometry antibody 
panel shown in Table 7.1 
 
Table 7. 1: Flow cytometry antibody panel used to assess lysosomal pH. 
Marker Fluorochrome Clone Manufacturer 
CD3 PE-Cy7 SK7 BD Bioscience 
CD14 APC M5E2 BD Bioscience 
CD19 BUV737 SJ25C1 BD Bioscience 
CD56 PE B156 BD Bioscience 
LysoSensor DND-189 FITC  Thermo Fisher 
 
 
7.2.1 Optimising pH measurement using the LysoSensor dye method 
The manufacturer’s handbook points out that prolonged incubation with the LysoSensor dye 
can increase the pH of lysosomes. To ensure that I avoided any potential confounding from 
this ‘alkalizing effect’ I performed an incubation time course experiment which confirmed that 
there was no change in the mean fluorescence intensity (MFI) from the dye for incubation times 
of 1 and 5 minutes (Figure 7.1). I then also investigated the effect of varying the interval 
between incubating cells with the dye and undertaking flow cytometric analysis, and found that 
there was no significant changes of MFI as long as the flow cytometry was completed within 
6 hours of the incubation (Figure 7.2). Finally, I also examined the effects of flow cytometry 
voltage setting and confirmed that inevitably the MFI from the LysoSensor dye was critically 
dependent upon the blue laser (FITC) voltage but was little affected by voltage for the FSC/SSC 
(forward-scatter/side-scatter) detectors (Figure 7.3). To avoid any confounding from variation 
in the blue laser voltage during the assessment of samples I included a Compbead standard and 
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measured the LysoSensor signal (lysosomal pH) relative to this. I found no significant change 
in the signal from the Compbeads when the amount of antibody or beads were varied (see 
Appendix). 
 
On the basis of these results I incubated antibody labelled PBMCs with LysoSensor dye for 5 
min and performed flow cytometry within 2 hours of this incubation. LysoSensor MFI 
measures were normalised with Compbeads (1 drop of Compbeads and 5 µL of standard 
antibody). 
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Figure 7. 2: LysoSensor MFI incubation to FACS analysis time course in T cells (A), NKT 
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7.3.1 Lysosomal pH in different cell subtypes 
To explore the influence of genotype on lysosomal pH I collected ex-vivo PBMCs from 60 
healthy donors recruited from Cambridge BioResource on the basis of genotype at rs74796499; 
30 protective allele carriers (7 protective allele homozygotes and 23 heterozygotes) and 30 
major allele (risk allele) homozygotes. For each subject, I measured Compbead normalised 
LysoSensor MFI in total T cells, NKT cells, NK cells, B cells and monocytes (all measures 
were made in triplicate). The average measure across all samples showed that lysosomal pH is 





























































Figure 7. 4: Mean Compbead normalised LysoSensor MFI in ex-vivo T cells, NKT cells, NK 
cells, B cells and monocytes (the more acidic the lysosomal pH the higher relative MFI). 
Histograms are based on the mean expression across all 60 samples with technical triplicates 




7.3.2 Cell subtype specific effects of the MS associated SNP rs74796499 on lysosomal pH 
The Cambridge BioResource supplied the genotype of rs74796499 for the 60 subjects 
considered, which I confirmed by independent genotyping. Genotype specific lysosomal pH 
measures are shown for each cell subtype in Figure 7.5. There was no evidence that this genetic 
variant is associated to the lysosomal pH in any of the ex-vivo cell subtypes considered. 
 






















H p = 0 .9 6 5 8
A























p = 0 .8 5 8 5
B























p = 0 .6 3 8 4
C























p = 0 .7 9 1 6
D























p = 0 .3 2 3 2
E
 
Figure 7. 5: rs74796499 genotype specific relative lysosomal pH in ex-vivo T cells (A), NKT 
cells (B), NK cells (C), B cells (D) and monocytes (E). Each measure is the average of three 
technical replicates.  
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7.3.3 Cell subtype specific effects of the IBD associated SNP rs3742704 on lysosomal pH 
Figure 7.6 shows the same data from Figure 7.5 stratified by the IBD associated SNP rs3742704. 
I found no evidence to support the suggestion that this SNP influences lysosomal pH.  
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Figure 7. 6: rs3742704 genotype specific relative lysosomal pH in ex-vivo T cells (A), NKT 
cells (B), NK cells (C), B cells (D) and monocytes (E). NB: In these 60 subjects there were no 





7.3.4 Cell subtype specific effects of the Sardinian GPR65 eQTL SNP rs3943657 on 
lysosomal pH 
Rather than directly measuring GPR65 expression in the ex-vivo cells, I instead genotyped the 
Sardinian GPR65 eQTL SNP rs3943657 which I had previously confirmed influences GPR65 
expression. Again, I saw no evidence that this SNP is associated with lysosomal pH (Figure 
7.7). 
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Figure 7. 7: rs3943657 genotype specific relative lysosomal pH in ex-vivo total T cells (A), 






7.3.5 The effect of activating GPR65 on lysosomal pH 
I next undertook a pilot study to explore the effects of extracellular acidosis and GPR65 
activation on lysosomal pH. In this experiment, I cultured PBMCs from three healthy 
volunteers for 18 hours in three settings. 
 
1) Normal physiological pH (pH=7.4) without any BTB09089 
2) Acidic pH (pH=6.2) without any BTB09089 
3)  Acidic pH (pH=6.2) with 20 μM BTB09089 
 
The LysoSensor MFI was generally lower at acidic pH than at physiological pH (except in the 
monocytes), indicating that extracellular acidity results in a higher (i.e. less acidic) lysosomal 
pH (Figure 7.8). Stimulation of GPR65 with 20 μM BTB09089, results in further lowering of 
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Figure 7. 8: Influence of extracellular pH and BTB09089 stimulation on LysoSensor MFI in T 
cells (A), NKT cells (B), NK cells (C), B cells (D) and monocytes (E). Each mean ± SD is 




In their study Lassen et al. [203] showed that lysosomal pH is significantly raised (less acidic) 
in GPR65 knockout mice and suggested that the GPR65 coding variant (rs3742704) that is also 
associated with increased risk of IBD, but more modestly, raises lysosomal pH and thereby 
disrupts lipid metabolism [203]. This SNP lies within a transmembrane domain of GPR65 and 
thus most likely alters GPR65 functioning by impairing intracellular signalling transduction 
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[152]. In my study I was unable to confirm the suggested effects of this SNP on lysosomal pH. 
It is possible that the effect of this IBD associated SNP may only be apparent in a cell subtype 
that I did not test, or perhaps is fully recessive and only occurs in risk allele (C/C) homozygotes, 
which were not included amongst the subjects I studied. It is also possible that perhaps this 
effect is too weak to detect with 60 subjects and that more individuals would need to be studied 
to provide enough power to confirm its presence.   
 
I also found no evidence that the MS associated SNP rs74796499 influences lysosomal pH in 
any of the cell subtypes from ex-vivo PBMCs. These data suggest that it is unlikely that 
rs74796499 exerts its effects on MS risk by altering lysosomal pH but leave in question whether 
perhaps the variant is only relevant when GPR65 is activated, by extracellular pH and/or its 
ligand. In a pilot study, I found evidence that both acidic extracellular pH and the synthetic 
GPR65 ligand (BTB09089) result in less acidic lysosomal pH. However, I was not able test 
whether these effects are influenced by the MS associated variant rs74796499. 
 
Altered lysosomal function has been described in MS, with fragile lysosomes observed in 
cerebral white matter from MS patients [313], and also excess lipid accumulation and increase 
autophagic activity seen in cortical neurons from MS patients [314, 315]. Furthermore, 
activation of lysosomal enzymes, including acid phosphatase and β-glucuronidase, has been 
confirmed in both lymphocytes and granulocytes during MS relapse [316]. In a recent study it 
was shown that exposure to psychosine disrupts lipid homeostasis and alters lysosomal pH 
[317]. Given the weight of evidence demonstrating the importance of GPR65 activity in 
determining lysosomal pH, and the profound effect of this pH on lysosomal function, it seemed 
logical to explore the effects of the MS associated variant on lysosomal pH. Unfortunately, I 





Chapter 8: LacCer and CD69 in a final cohort 
 Introduction 
In Chapter 6, I extended the evidence indicating that carrying the protective allele at 
rs74796499 increases the surface expression of CD69 on T cells cultured in an acid 
environment. However, this effect was only apparent in unstimulated cultures, despite the 
substantial increase in the expression of CD25 and CD69 induced by stimulation with anti-
CD3/CD28 antibodies. Furthermore, although the GPR65 agonist BTB09089 significantly 
reduced the expression induced by anti-CD3/CD28 stimulation I found no evidence that 
genotype influenced the final level of expression regardless of extracellular pH. In these earlier 
experiments, I did not consider the effects of BTB09089 in unstimulated cultures as I had 
wrongly anticipated that the effect of the genotype would be stronger in stimulated cultures 
and therefore it would be easier to establish the involvement of GPR65 in the context of 
stimulation. In this chapter I therefore wanted to explore the effect of BTB09089 in the 
unstimulated cultures where there was an apparent effect of genotype on CD69 expression. In 
this chapter I also wanted to extend the analysis to include individuals that are homozygous for 
the protective allele at rs74796499; I had not tested these in my previous work, raising the 
possibility that I could have missed recessive protective effects, as have been observed with 
variation in the TYK2 gene [318]. The main reason for not considering these before was the 
practical difficulty of finding such individuals. The low frequency of the rs74796499 protective 
allele in the UK population (1.6%; 1000 Genomes Project Phase 3) means that only 
approximately 3 in 10,000 subjects are homozygous for this allele; which means that even in a 
large cohort like the Cambridge BioResource there are only a modest number of such subjects 
who might be willing to be involved in research. Given that CD69 expression has been shown 
to alter the balance between pro-inflammatory Th17 cell and anti-inflammatory Treg cells [301, 
319], I also wanted to extend my experiments to explore whether the genotype dependent 
changes in CD69 expression that I had observed previously were accompanied by any changes 
in the ratio of these T cell subtypes. Unfortunately, the costs associated with undertaking such 
an analysis using the necessary surface markers were prohibitive, however, I was able to 
explore the mRNA expression of the key Th17 transcription factor, RORC. Furthermore, in 
Chapter 6 I found evidence suggesting that protective allele of rs74796499 was associated with 
lower expression of the glycosphingolipid LacCer (CD17) in ex-vivo cells. However, despite 
the evidence from IBD that genetic variation in GPR65 can alter glycosphingolipid metabolism 
by changing lysosomal pH [320] I found no evidence that rs74796499 exerts any such effect 
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on the pH in these organelles (see Chapter 7, the work in Chapter 7 was performed in parallel 
to the work described in this chapter and employed the same samples – including the protective 
allele homozygotes). Finally, in this chapter I wanted to assess the expression of LacCer in 
cultured cells (with and without BTB09089 stimulation) as well as ex-vivo cells. 
 
To undertake this next phase of my work I established two flow cytometry antibody panels, the 
first to assess the expression of CD69 and LacCer in ex-vivo cells (Table 8.1) and the second 
to assess the expression of CD69 and LacCer in unstimulated cultured cells at normal (pH=7.4) 
and acidic (pH=6.2) conditions both with and without exposure to BTB09089 (Table 8.2). 
 
Table 8. 1: Flow cytometry panel for assessing ex-vivo cells. 
Marker Fluorochrome Clone Manufacturer 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 BUV395 RPA-T4 BD Bioscience 
CD8 APC RPA-T8 BD Bioscience 
CD17 FITC Huly-m13 LifeSpan Biosciences 
CD19 BUV737 SJ25C1 BD Bioscience 
CD56 PE B156 BD Bioscience 
CD69 v450 FN50 BD Bioscience 
 
 
Table 8. 2: Flow cytometry for assessing cultured cells. 
Marker Fluorochrome Clone Manufacturer 
CD3 PE-Cy7 SK7 BD Bioscience 
CD4 BUV395 RPA-T4 BD Bioscience 
CD8 APC RPA-T8 BD Bioscience 
CD17 FITC Huly-m13 LifeSpan Biosciences 
CD19 BUV737 SJ25C1 BD Bioscience 
CD56 PE B156 BD Bioscience 
CD69 v450 FN50 BD Bioscience 





 Extending the analysis of LacCer expression 
8.2.1 LacCer in ex-vivo PBMC subtypes 
As lipid rafts are essential in all cells I first measured LacCer expression in a range of ex-vivo 
PBMC subtypes, including T cells, CD4+ T cells. CD8+ T cells, NKT cells, NK cells, B cells, 
classic monocytes (CD14+ CD16-) and non-classic monocytes (CD14+ CD16+) (Figure 8.1), 
in order to establish to what extent each of these express this molecule. Interestingly, LacCer 
was most highly expressed in monocytes (nearly 100%) and I therefore decide to not include 







































































































Figure 8. 1: Expression of LacCer on the surface of ex-vivo PBMC subtypes. Samples (n=2) 
with 3 technical replicates.  
 
 
 Refining the use of GPR65 ligands 
Before embarking on the main work described in this chapter I wanted to establish if it would 
be possible to use the naturally occurring GPR65 ligand psychosine rather than its synthetic 
agonist BTB09089. Unlike BTB09089, which is an agonist of GPR65 [193], psychosine is an 
antagonist [183], and would therefore be expected to reduce the effects of acidic pH rather than 
mimic these effects. Furthermore, as psychosine is highly toxic to cells its utility might be 
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limited by its toxic effects; it is believed that most of the neurodegeneration seen in Krabbe’s 
disease results from the toxic effects of psychosine [295]. Like BTB09089, psychosine is 
hydrophobic but can be solubilised using DMSO. 
 
8.3.1 Considering psychosine as a GPR65 antagonist 
In order to establish what concentrations of psychosine might have toxic effects in my culture 
systems I first stimulated PBMCs with anti-CD3/CD28 antibodies in acidic conditions (pH=6.2) 
for 18 hours in the presence of differing concentrations of psychosine between 0 μM to 20 μM. 
At concentrations below 1 μM there was very little change in the proportion of cells falling 
within a lymphocyte gate, however at concentrations above 10 μM the proportion fell 
significantly presumably as a result of cell death (Figure: 8.2). 
Figure 8. 2: Proportion of cells within a lymphocyte gate after 18 hours of stimulated culture 
in the presence of differing psychosine concentrations. 
 
Having established that psychosine seemed to have little toxicity at concentrations below 1 μM 
but was clearly toxic at concentrations above 10 μM, I set up further PBMC cultures in the 
0 μM 0.01 μM 0.1 μM 
1 μM 10 μM 20 μM 
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presence of psychosine concentrations up to a maximum of 5 μM. In these experiments I set 
up unstimulated and anti-CD3/CD28 stimulated PBMC cultures in acidic conditions (pH=6.2) 
and measured the proportion of LacCer and CD69 positive cells in a range of cell subtypes 
after 18 hours of culture. There was little effect of anti-CD3/CD28 stimulation on LacCer 
expression (Figure 8.3) and the expected increase in expression of CD69 was seen (Figure 8.4). 
At concentrations of 1 μM and below psychosine seemed to have little effect on the expression 
of LacCer or CD69. Whereas at a concentration of 5 μM the expression of LacCer was notably 
increased in all tested cell subtypes, while the expression of CD69 was generally little changed. 
These effects are in contrast to the inhibitory effects of BTB09089 and thus in keeping with an 
antagonistic effect of psychosine. However, at this concentration the toxic effects of psychosine 
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Figure 8. 3: LacCer expression in cell subtypes from PBMC cultures with and without anti-
CD3/CD28 stimulation at a range of psychosine concentrations between 0 μM to 5 μM. 
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Figure 8. 4: CD69 expression in cell subtypes from PBMC cultures with and without anti-
CD3/CD28 stimulation at a range of psychosine concentrations between 0 μM to 5 μM. 
Measures were made from each sample (n=2) in triplicate. 
 
These experiments thus show that unfortunately non-toxic levels of psychosine had no major 
effect on expression. At higher (toxic) levels of psychosine increased expression but could not 
be reliably distinguished from toxic effects of psychosine. Based on these data and the report 
that psychosine might also influence GPR4 and OGR1 [183], I decided to continue using the 
synthetic ligand BT09089 which has no toxic effects at concentrations sufficient to activate 
GPR65.  
 
8.3.2 LacCer and CD69 expression on dead cells 
The observation that toxic concentrations of psychosine results in increased levels of LacCer 
suggested that perhaps dead or dying cells have increased expression of this marker. To 
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investigate this possibility, I cultured PBMCs for 18 hours (without stimulation) under acidic 
(pH=6.2) and physiological (pH=7.4) conditions both with and without BTB09089, and then 
compared LacCer (and CD69) expression in live and dead cells; dead cells were identified 
using fixable viability dye as described previously. As anticipated from the work described in 
Chapter 4 only very low levels of dead cells were seen (4-6% of FACS captured events), 
however a very much proportion of dead cells expressed LacCer although the proportion that 
express CD69 is little different (Figure 8.5). Given the prominent expression of LacCer on dead 
cells I excluded such cells from used all my subsequent experiments using a live-dead stain.  
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Figure 8. 5: Comparison of LacCer (A) and CD69 (B) expression in live and dead T cells after 
18 hours of culture (unstimulated) at pH 6.2 (Left) and pH 7.4 (Right). Measures were made 





 Reassessing the effects of rs74796499 genotype on the expression of 
LacCer and CD69 
In order to search for genotype dependent effects on the expression of LacCer and CD69, a 
total of 60 healthy donors were recruited from the Cambridge BioResource on the basis of their 
rs74796499 genotype; including 7 protective allele homozygotes (A/A), 23 heterozygotes (A/C) 
and 30 risk allele homozygotes (C/C) (these are the same subjects considered in Chapter 7). 
These individuals were recruited and sampled in pairs with the protective allele carrier (A/A or 
A/C) always paired with a risk allele homozygote (C/C). As before I was blind to sample 
genotypes until all experiments were completed and measures finalised. In total 139 
phenotypes were tested for association with genotype. However, since many of these are 
necessarily correlated the effective number of independent phenotypes was again established 
using the R script provided by Prof Frank Dudbridge (using 10,000 permutations). This script, 
established that the effective number of independent phenotypes was 60 and I therefore set a 
threshold of p<0.00083 for declaring statistical significance in order to correct for multiple 
testing. 
 
Figure 8.6 shows the mean expression of LacCer and CD69 across these 60 samples in each 
ex-vivo lymphocyte subtype; T cells, CD4+ T cells, CD8+ T cells, NKT cells, NK cells and 
B cells. This figure show that the highest expression of LacCer is seen on B cells and NKT 











































































































































Figure 8. 6: Mean proportion of ex-vivo lymphocyte subtypes expressing LacCer and CD69. 
Sample specific expression was measured in duplicate. 
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Figures 8.7 and 8.8 show the mean proportion of lymphocyte subtypes expressing LacCer and 
CD69 after unstimulated culture, with and without BTB09089, in acidic (pH=6.2) and 
physiological (pH=7.4) environments. In contrast to the preliminary observations shown in 
Figure 8.2 this much larger data set shows that in fact BTB09089 tends to increase the 
expression of LacCer in all lymphocyte subtypes although this effect is only notable in NKT 
cells from acidic culture conditions (Figure 8.7). For CD69 the preliminary observations were 
largely reproduced apart from in NK cells where BTB09089 may slightly increase CD69 
expression (Figure 8.8). Interestingly BTB09089 seems to have relatively little effect on the 
expression of either moiety at physiological pH, which is of course slightly alkaline of neutral 
(Figures 8.7 and 8.8). As anticipated BTB09089 had no meaningful effect on the proportion of 
dead cells after culture. 
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Figure 8. 7: Mean LacCer expression across all 60 individuals in lymphocyte subtypes after 
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Figure 8. 8: Mean CD69 expression across all 60 individuals in lymphocyte subtypes after 
culture. Sample specific expression was measured in triplicate. 
 
8.4.1 Ex-vivo lymphocyte subtypes 
Unfortunately, in this replication set I found no evidence that the protective allele of 
rs74796499 (A) has any effect on the expression of LacCer in any of the ex-vivo lymphocyte 
subtypes (Figure 8.9). These data indicate that the nominally significant observation that 
carrying the protective allele reduced expression of LacCer was a false positive finding. As 
anticipated there was no evidence that genotype influenced the expression of CD69 expression 
in any of the ex-vivo lymphocytes subtypes (Figure 8.10). Similarly, I found no evidence that 
the rs74796499 genotype influenced the balance of CD4+ T and CD8+ T cells in ex-vivo 
lymphocytes (Figure 8.11). Association analysis for the rs74796499 SNP was completed using 
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Figure 8. 9: LaCer expression on ex-vivo lymphocyte subtypes by genotype at rs74796499: 
protective allele homozygotes (A/A), heterozygotes (A/C) and risk allele homozygotes (C/C) 
are compared for total T cells (A), CD4-CD8- T cells (B), CD4+ T cells (C), CD8+ T cells (D), 
NKT cells (E), CD8+ NKT cells (F), NK cells (G) and B cells (H). 
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Figure 8. 10: CD69 expression on ex-vivo lymphocyte subtypes by genotype at rs74796499; 
protective allele homozygotes (A/A), heterozygotes (A/C) and risk allele homozygotes (C/C) 
are compared for total T cells (A), CD4-CD8- T cells (B), CD4+ T cells (C), CD8+ T cells (D), 
NKT cells (E), CD8+ NKT cells (F), NK cells (G) and B cells (H). 
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Figure 8. 11: Proportion of T cells that are CD4+ (A) or CD8+ (B) and the ratio of CD4+/CD8+ 
T cells (C) in protective allele homozygotes (circles), heterozygotes (inverted triangles) and 




8.4.2 LacCer expression after culture 
Figures 8.12, 8.13, 8.14, 8.15, 8.16, 8.17, 8.18 and 8.19 show LacCer expression by 
rs74796499 genotype in acidic (pH=6.2) and physiological (pH=7.4) conditions for total T 
cells, CD4-CD8- T cells, CD4+ T cells, CD8+ T cells, NKT cells, CD8+ NKT cells, NK cells 
and B cells respectively. As for ex-vivo cells I found no evidence to support any influence of 
the MS associated SNP rs74796499 on LacCer expression.  
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Figure 8. 12: Expression of LacCer on total T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
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Figure 8. 13: Expression of LacCer on CD4- CD8- T cells (“double negative” cells) in 
protective allele homozygotes (circles), heterozygotes (inverted triangles) and risk allele 
homozygotes (squares) after 18 hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 14: Expression of LacCer on CD4+ T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 15: Expression of LacCer on CD8+ T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 16: Expression of LacCer on NKT cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 17: Expression of LacCer on CD8+ NKT cells in protective allele homozygotes 
(circles), heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 
hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 18: Expression of LacCer on NK cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
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Figure 8. 19: Expression of LacCer on B cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 





8.4.3 CD69 expression after culture 
Figures 8.20, 8.21, 8.22, 8.23, 8.24, 8.25, 8.26 and 8.27 show CD69 expression by rs74796499 
genotype in acidic (pH=6.2) and physiological (pH=7.4) conditions for total T cells, CD4-CD8- 
T cells, CD4+ T cells, CD8+ T cells, NKT cells, CD8+ NKT cells, and NK cells and B cells 
respectively. Unfortunately, here I saw a trend towards greater expression of CD69 in 
protective allele carriers from cells cultured in acidic conditions (unstimulated) but this was 
not even nominally significant. This failure of replication suggests that these previous 
observations were also false positives.  
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Figure 8. 20: Expression of CD69 on total T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 21: Expression of CD69 on total CD4- CD8- T cells (“double negative” cells) in 
protective allele homozygotes (circles), heterozygotes (inverted triangles) and risk allele 
homozygotes (squares) after 18 hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 22: Expression of CD69 on total CD4+ T cells in protective allele homozygotes 
(circles), heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 
hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 23: Expression of CD69 on total CD8+ T cells in protective allele homozygotes 
(circles), heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 
hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 24: Expression of CD69 on total NKT cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 25: Expression of CD69 on total CD8+ NKT cells in protective allele homozygotes 
(circles), heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 
hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 26: Expression of CD69 on total NK cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 27: Expression of CD69 on B cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) after 18 hours culture 
at pH 6.2 and pH 7.4 with and without BTB09089. 
 
 Second independent MS associated variant - rs11052877 
Genotyping rs11052877 in the 60 individuals studied above revealed that this cohort included 
17 protective allele homozygotes (A/A), 35 heterozygotes (A/G) and 8 risk allele homozygotes 
(G/G). As in Chapter 6 I did not include recruitment pair specific covariates in the analysis of 
this SNP. For SNPs other than rs74796499 many of the recruitment pairs have the same 
genotype and therefore including these covariates would effectively exclude these pairs and 
thereby reduces the power of the analysis. Figure 8.28, 8.29, 8.30, 8.31, 8.32, 8.33, 8.34, 8.35, 
and 8.36 show CD69 expression by rs11052877 genotype in ex-vivo and cultured cells. 
Although no association surviving correction for multiple testing was seen, nominally 
significant association was seen for the higher expression of CD69 in those individuals carrying 
the rs11052877 protective allele. 
In addition, no significant associations were seen with any of the other SNPs tested in Chapter 
6 (rs1163251, rs17785991, rs28533072, rs3742074, rs3943657 and rs6020055). 
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Figure 8. 28: CD69 expression on ex-vivo lymphocyte subtypes by genotype at rs11052877; 
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Figure 8. 29: Expression of CD69 on total T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) for rs11052877 after 
18 hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 30: Expression of CD69 on CD4- CD8- T cells (“double negative” cells) in protective 
allele homozygotes (circles), heterozygotes (inverted triangles) and risk allele homozygotes 
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Figure 8. 31: Expression of CD69 on CD4+ T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) for rs11052877 after 
18 hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 32: Expression of CD69 on CD8+ T cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) for rs11052877 after 
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Figure 8. 33: Expression of CD69 on NKT cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) for rs11052877 after 
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Figure 8. 34: Expression of CD69 on CD8+ NKT cells in protective allele homozygotes 
(circles), heterozygotes (inverted triangles) and risk allele homozygotes (squares) for 
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Figure 8. 35: Expression of CD69 on NK cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) for rs11052877 after 
18 hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
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Figure 8. 36: Expression of CD69 on B cells in protective allele homozygotes (circles), 
heterozygotes (inverted triangles) and risk allele homozygotes (squares) for rs11052877 after 
18 hours culture at pH 6.2 and pH 7.4 with and without BTB09089. 
 
 
 mRNA expression in ex-vivo cells 
I collected mRNA from CD3+ and CD3- ex-vivo cells and measured transcriptional expression 
of GPR65 using two primer pairs. Primer pair 1 (also be used in Chapter 6) extends from exon 
1 to exon 2 and therefore includes the exon 1-2 boundary; whereas primer pair 2 is contained 
entirely within exon 2 (this pair is distinct from the primers used in Chapter 6). Figure 8.37 
shows the results for both primer pairs in both cell subtypes, which reveals a trend (nominally 
significant in CD3- cells) towards higher expression of GPR65 in individuals carrying the 
protective allele. The same trend was seen in Chapter 6, but no protective allele homozygotes 
were included in that earlier analysis. However, after conditioning these data on the known 
eQTL rs3943657 there was no residual evidence of association, confirming that this modest 
apparent association with expression is the result of LD between rs74796499 and rs3943657 
(D’=1.0 in the CEU population, with the minor allele of rs74796499 always carried on 
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chromosomes carrying the major allele at rs3943657, the difference in allele frequency means 
that r2 is necessarily low). In addition, I also measured the mRNA expression of GALC, CD69, 
RORC and non-coding RNA LINC01146 (Figure 8.38) and found evidence that carrying the 
protective allele of rs74796499 increased the expression of GALC and CD69; again these 
effects disappeared after conditioning rs3943657. All expressions levels were quantified 
relative to the housekeeping gene β-ACTIN using the standard curve method. Analysis was 
performed as for surface expression but with additional covariates related to batching for RNA 
extraction, RNA clean-up and cDNA conversion. 
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Figure 8. 37: GPR65 mRNA expression using primer pair 1 (top row) and primer pair 2 (bottom 
row) in CD3+ (left hand panels) and CD3- cells (right hand panels) comparing rs74796499 
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Figure 8. 38: GALC (A), CD69 (B) and RORC (C) and LINC01146 (D) mRNA expression in 
CD3+ (left hand panels) and CD3- cells (right hand panels) comparing rs74796499 protective 





8.6.1 GPR65 expression and rs3943657 
Given that rs3943657 is an established eQTL for GPR65 [271], I genotyped this SNP in these 
60 individuals and tested for association with the data from both GPR65 primer pairs as a 
positive control (Figure 8.39). The result was as expected with lower expression of the minor 
allele (G) (and the clearest difference seen for primer pair 1 in CD3- cells). Pair IDs were not 
included as covariates. 
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Figure 8. 39:  GPR65 mRNA expression using primer pair 1 (top row) and primer pair 2 
(bottom row) in CD3+ (left hand panels) and CD3- cells (right hand panels) comparing 
rs3943657 minor allele homozygotes (circles, n=6), heterozygotes (inverted triangles, n=18) 







In this final stage of my thesis I unfortunately failed to replicate either of the observations I had 
made earlier regarding the effects of carrying the protective allele of rs74796499; lower levels 
of LacCer in ex-vivo cells and higher level of CD69 on cells cultured in acidic conditions. 
There are several factors that may have confounded this final round of experiments, in 
particular technical effects relating to differences in the flow cytometry antibody panel used 
and the possibility of regression to the mean. However, the evidence supporting these effects 
from my earlier work was rather preliminary, only just surviving correction for multiple testing, 
and thus these earlier observations are most likely to have been false positive associations. The 
fact that I saw the expected effect of rs3943657 on the mRNA expression of GPR65 provides 
a positive control indicating that my study had adequate power. However, it is clear that I would 
need a very much larger study to definitively confirm or refute whether or not the effects I 
highlighted in earlier chapters are genuine.  
 
The low frequency of the rs74796499 protective allele meant that it became increasingly 
difficult for the Cambridge BioResource to recruit completely healthy volunteers and in the 
final set of experiments described in this chapter a small proportion of those recruited were 
receiving treatments for immunologically minor conditions, such as depression and eczema. 
Those receiving treatment for such conditions (e.g. anti-histamine, anti-depressants etc.) were 
over represented in the protective allele carriers (the more difficult group to recruit) and 
therefore it is conceivable that these could have confounded my results. However, it seems 
unlikely that such treatments would have undermined the demonstration of both of these effects, 
especially the increase in CD69 seen in cultured cells, where it seems unlikely that any drug 
related effects would have persisted. 
 
Because I did not observe any evidence for genotype dependent effects on expression (as had 
been suggested by the work in earlier chapters) it was not possible to infer whether GPR65 
might be involved through the effects of BTB09089. I confirmed the toxic effect of psychosine 
reported by others [159, 321] and saw substantial effects of BTB09089 on surface expression 
in cultured cells which certainly suggests that GPR65 is involved in modulating the response 
of immune cells in acidic conditions, but the relevance of this to the modulation of MS risk 
resulting from rs74796499 genotype cannot be inferred.  
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Chapter 9: Conclusion and Future work 
The research I undertook during my PhD was prompted by my predecessor’s provisional 
observations that extracellular pH influences T cell activation and that the extent of this 
influence was dependent upon MS associated variation on chromosome 14q31.3 [33, 151]. 
Given the known immune regulatory effects and acid sensing properties of GPR65 [193], I 
hypothesised that this gene might be involved in mediating these effects. It seems reasonable 
to imagine that acid induced activation of GPR65 might have an important role in limiting the 
inflammatory response within MS lesions, and therefore that the allele carried at the nearby 
MS associated SNP rs74796499 might exert its effects on risk by altering GPR65’s 
involvement in this process. Unfortunately, although, I was able to confirm with high statistical 
confidence that T cell activation is indeed affected by extracellular pH, I found no evidence to 
support the suggestion that rs74796499 genotype influences these effects. 
 
In his original pilot work my predecessor, Dr Tom Button, only considered the late activation 
marker CD25. However, in my experiments I also assessed the early activation marker CD69 
and the functionally important membrane lipid lactosylceramide (LacCer, CD17). This 
extended analysis revealed that the expression of CD69 is increased after culturing in acidic 
conditions, even in the absence of any stimulation. In my initial experiments I found evidence 
that rs74796499 genotype might influence this acid induced expression of CD69, and also the 
expression of LacCer in ex-vivo cells. Unfortunately, neither of these nominally significant 
provisional trends were confirmed in my replication experiments. Including BTB09089, the 
synthetic agonist of GPR65, in cultures dramatically changed the expression of CD25, CD69 
and LacCer in a range of cell types, but once again did not reveal any genotype dependent 
effects. In total despite processing samples from over 160 individuals I found no convincing 
evidence that the genotype at the MS associated SNP rs74796499 exerts any effects on 
lymphocyte activation, regardless of pH, anti-CD3/CD28 stimulation or GPR65 activation. 
 
My research was based exclusively on samples from healthy volunteers recruited through the 
Cambridge BioResource. This increased the power of my analysis by ensuring higher than 
expected representation of the lower frequency genotypes, but meant that I have not assessed 
the influence of rs74796499 in the context of the disease. I had intended to extend my work 
into considering patient samples once a genotype dependent effect was demonstrated but in 
retrospect I probably should have included patient samples in parallel with healthy controls. It 
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is possible that genotype dependent effects might have emerged if I had sufficient resources to 
consider alternate GPR65 negative modulators, such as ZINC62678696 [322], more refined 
cell subtypes, such as iNKT cells [323-325], or had measured cytokine profiles, for example 
by using the human Th1/Th2/Th17A cytokine kit (BD Bioscience, US) (which including IL-2, 
IL-4, IL-5, IL-10, TNF, IFN-γ and IL-17A). It might also have been profitable to further 
explore the effects of genotype on apoptosis, especially since GPR65 has already been shown 
to have a functionally important role in the survival and apoptosis in other cell types and disease 
contexts [185, 326]. In my experiments I only employed a simple fixable viability stain so that 
dead cells could be excluded. It could have been relevant to extend the analysis to include a 
fuller assessment of survival and apoptosis. 
 
Given more time I would like to have further optimised and refined my efforts to localise and 
quantify GPR65 which would also have enabled me to explore the effects of knocking down 
this gene. The fact that I easily replicated the eQTL effects of rs3943657 confirms the validity 
of my RNA quantification [271].  
 
Given the importance of CD69 signalling in establishing the balance between pro inflammatory 
(Th17) and anti-inflammatory (Treg) cells [237, 301, 302, 319], even though I saw no evidence 
that rs74796499 genotype influences the expression of RORC in ex-vivo lymphocytes I think 
it would have been interesting to also consider this key transcription factor in cultured cells. 
Considering the Treg master transcription factor FOXP3 could also have been informative. 
 
I found no evidence that either the MS associated SNP rs74796499 [151] or the IBD associated 
SNP rs3742704 [320] influences lysosomal pH. However, lysosomes are highly heterogeneous, 
so it might be that genotype is only relevant in some of the individual classes of lysosome. It 
would also have been interesting to try and establish a way to use the dual dye LysoSensor 
system so that absolute, rather than relative, pH could have been measured. 
 
In my research I established a culture system capable of maintaining a stable pH and used this 
to explore the influence of extracellular pH on human T cell activation. I found marked effects 
of pH on the expression of both early (CD69) and late (CD25) activation markers, and also, 
unexpectedly, observed that in an acid environment the expression of CD69 increased even 
without stimulation. Unfortunately, I could find no evidence to support my predecessor’s 
suggestion that the MS associated variant rs74796499 influenced these processes. His 
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preliminary data nominated the acid sensing receptor GPR65 as the candidate gene in this 
region but unfortunately, I have not been able to find any GPR65 dependent effects that are 
influenced by the MS associated SNP. The lead MS associated variant, rs74796499, is in tight 
LD with a coding variant in the other protein coding gene from this region, GALC. This 
synonymous coding variant is predicted to be a splice variant and so the role of GALC should 
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